Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Critical Care Medicine›Condition·Updated Jul 11, 2026·v1

Septic Shock

Septic shock is the most severe manifestation of sepsis, defined by vasopressor-dependent hypotension and elevated lactate despite volume resuscitation. Management hinges on a time-critical bundle: broad-spectrum antibiotics within 1 hour, balanced crystalloid 30 mL/kg, early norepinephrine targeting MAP 65-70 mm Hg, and source control within 12 hours. Balanced crystalloids, CRT-guided resuscitation, and early addition of vasopressin in refractory cases reduce organ failure. Harmful practices include high MAP targets in the elderly, HES administration, and routine use of unproven adjuncts. Delayed RRT is safe, and the ABCDEF bundle promotes liberation and reduces post-intensive care syndrome.

High Evidence462 references·2,269 words·10 min read·v1
septic shocksepsiscritical carevasopressornorepinephrinelactateSurviving Sepsis Campaigndistributive shockorgan dysfunctionresuscitationsource controlABCDEF bundle

Quick Reference

RxDrug of choice[[Norepinephrine]], first-line vasopressor, titrate to MAP 65-70 mm Hg. Start early to improve shock control.
AltAlternatives[[Vasopressin]] (add at norepinephrine >0.25-0.5 µg/kg/min), [[Epinephrine]] (third-line, 0.05-0.5 µg/kg/min), [[Hydrocortisone]] 50 mg IV q6h ± [[Fludrocortisone]] 50 µg daily for refractory shock.
⊘Avoid[[Hydroxyethyl starch]] (HES), increases AKI and mortality. High-target MAP (80-85 mm Hg) in patients aged ≥65 years, increases mortality (OPTPRESS). [[Drotrecogin alfa]], no benefit, increased bleeding. Tight glycemic control (80-110 mg/dL), severe hypoglycemia.
DxTest of choiceSerum lactate (required for Sepsis-3 definition; repeat in 2-4 h), blood cultures (before antibiotics), and point-of-care ultrasound (POCUS) to assess shock type and fluid responsiveness.
ScKey score[[SOFA]] score (organ dysfunction in ICU; AUROC 0.74 for in-hospital mortality) and [[qSOFA]] (≥2: altered mentation, RR ≥22, SBP ≤100, predicts poor outcomes in non-ICU settings).
→When to referRefractory shock despite norepinephrine >0.5 µg/kg/min and vasopressin, need for advanced source control (surgical drainage, debridement), requirement for RRT or mechanical ventilation, or absence of ICU capability for escalation (high-volume center preferred).
Septic shock is a medical emergency requiring immediate recognition, broad-spectrum antibiotics within 1 hour, balanced crystalloid 30 mL/kg, and norepinephrine to MAP 65-70 mm Hg. Source control within 12 hours and daily de-escalation of therapy reduce mortality. Avoid high MAP targets in the elderly, harmful fluids (HES), and unproven adjuncts (vitamin C, tight glycemic control).
Septic shock is a life-threatening subset of sepsis defined by persistent hypotension requiring vasopressors and lactate >2 mmol/L after fluid resuscitation, carrying hospital mortality >40% [20,44]. It is the leading cause of death in non-cardiac ICUs globally. Rapid recognition, broad-spectrum antibiotics within 1 hour, and protocolized resuscitation are critical to improve outcomes.

Overview and Recommendations

Background

  • •Septic shock accounts for ~10% of ICU admissions globally and carries a hospital mortality of 37-51%, depending on severity and setting. The Sepsis-3 definition operationalizes the diagnosis as a vasopressor requirement to maintain MAP ≥65 mm Hg and serum lactate >2 mmol/L after adequate fluid resuscitation, a combination that selects a cohort with mortality >40%.
  • •The pathophysiology centers on infection-triggered vasoplegia, capillary leak, and maladaptive immune activation. Pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) drive widespread endothelial injury, nitric oxide-mediated vasodilation, and relative hypovolemia, resulting in distributive shock.
  • •Septic shock represents the most severe end of the sepsis continuum, with pooled ICU mortality of 37.3% in recent meta-analyses. Mortality has declined from ~47% in the early 1990s to ~29% by the late 2000s, attributed to improved recognition, protocolized care, and the adoption of Surviving Sepsis Campaign (SSC) bundles.
  • •The lung is the dominant source of infection (~68%), followed by the abdomen (~27%) and bloodstream (~8%). Source is a powerful independent predictor of outcome: ischemic bowel carries 75% hospital mortality, whereas obstructive uropathy carries only 26%.
  • •The four pillars of early management, antibiotics within 1 hour, 30 mL/kg crystalloid, norepinephrine to MAP 65-70 mm Hg, and source control within 12 hours, are supported by landmark trials: ARISE, ProCESS, ProMISe, SEPSISPAM, OPTPRESS, and ANDROMEDA-SHOCK.

Evaluation

  • •Suspect septic shock in any patient with suspected infection who presents with hypotension (MAP <65 mm Hg) or serum lactate ≥2 mmol/L. Altered mental status, tachypnea, and unexplained organ dysfunction are red flags, especially in the elderly or immunocompromised, who may present with hypothermia or confusion.
  • •Ask about fever, chills, dyspnea, cough, abdominal pain, dysuria, and recent antibiotic or healthcare exposure. In immunocompromised patients, infection may be afebrile; elicit symptoms of opportunistic infections.
  • •Examine vital signs and peripheral perfusion. Measure capillary refill time (CRT) by pressing the pulp of the index finger for 5 seconds; a CRT >3 seconds indicates tissue hypoperfusion and is a strong predictor of 24-hour mortality (AUC 0.829). Assess skin mottling (score 0-5 from knees to periphery); a score ≥2 at 6 hours carries a 16-fold higher odds of 14-day mortality, and score ≥4 carries a 74-fold increase.
  • •Order a serum lactate immediately. A lactate >2 mmol/L (≥4 mmol/L indicates severe tissue hypoperfusion) is required for the Sepsis-3 shock definition and must be repeated within 2-4 hours to assess clearance. Obtain blood cultures (aerobic and anaerobic) before antibiotics if this does not delay therapy beyond 1 hour.
  • •Perform point-of-care ultrasound (POCUS) to exclude obstructive shock (tamponade, tension pneumothorax, massive PE), assess left and right ventricular function (LV systolic dysfunction in up to 63%, RV dysfunction in 48%, associated with 3-fold higher mortality), and evaluate fluid responsiveness using passive leg raise or IVC collapsibility.
  • •Use the Sepsis-3 criteria to confirm the diagnosis: vasopressor requirement to maintain MAP ≥65 mm Hg and serum lactate >2 mmol/L after at least 30 mL/kg of crystalloid. This distinguishes septic shock from sepsis alone and from other forms of shock.
  • •In non-ICU settings, screen with qSOFA: ≥2 of altered mentation, respiratory rate ≥22/min, systolic BP ≤100 mm Hg. qSOFA has lower sensitivity (65%) but high specificity (92%) for predicting in-hospital mortality, outperforming SIRS criteria.
  • •Order additional laboratory studies: complete blood count (leukocytosis or leukopenia, thrombocytopenia), coagulation profile (PT, aPTT, fibrinogen, D-dimers for DIC screening), procalcitonin (moderate diagnostic accuracy; not diagnostic alone but supportive when >10 ng/mL strongly predicts need for invasive support), and basic metabolic panel (renal function, electrolytes, glucose).
  • •Obtain imaging to identify the source of infection: chest X-ray or CT for pneumonia, abdominal CT or ultrasound for intra-abdominal infection, and consider dedicated imaging based on clinical suspicion.
  • •Serial lactate measurement, CRT reassessment, and trending of the mottling score guide the response to resuscitation. The ANDROMEDA-SHOCK-2 trial (2025) confirmed that a personalized protocol targeting CRT (≤3 seconds) is superior to usual care for a composite outcome (win ratio 1.16).

Management

  • •Initiate the 1-hour bundle immediately upon recognition: draw blood cultures, measure lactate, start broad-spectrum antibiotics (within 1 hour of recognition), and begin IV crystalloid at 30 mL/kg. Each hour delay in antibiotics increases mortality (OR 1.04 per hour).
  • •Administer balanced crystalloids (lactated Ringer’s or PlasmaLyte) over 0.9% saline. The SMART trial showed balanced solutions reduce 30-day mortality in sepsis (26.3% vs 31.2%; aOR 0.74; NNT=20) and major adverse kidney events. In pediatric patients, PlasmaLyte lowers new/progressive AKI (RR 0.62; NNT=8).
  • •Start norepinephrine as the first-line vasopressor, titrated to a MAP target of 65-70 mm Hg. Initiate early (within 90 minutes of ED arrival) to improve shock control (76.1% vs 48.4% at 6 hours; NNT=3.6). Compared with dopamine, norepinephrine causes fewer arrhythmias (12.4% vs 24.1%; NNH=8.6).
  • •Avoid targeting a high MAP (80-85 mm Hg) in patients aged ≥65 years: the OPTPRESS trial found significantly increased 90-day mortality (39.3% vs 28.6%; NNH=9.3), regardless of chronic hypertension status.
  • •Add vasopressin (0.01-0.06 U/min) as a second-line agent when the norepinephrine dose exceeds 0.25-0.5 μg/kg/min. The VANISH trial showed vasopressin reduces renal replacement therapy (RRT) use (25.4% vs 35.3%; NNT=10.1).
  • •For refractory shock requiring high-dose norepinephrine, add epinephrine (0.05-0.5 μg/kg/min) or start hydrocortisone 50 mg IV every 6 hours plus fludrocortisone 50 μg daily (APROCCHSS regimen). Hydrocortisone alone (ADRENAL) did not reduce 90-day mortality, but the combination reduced it from 49.1% to 43.0% (NNT=16.4).
  • •Achieve source control within 12 hours of diagnosis, drain abscesses, remove infected catheters, debride necrotic tissue, and surgically repair perforated viscera. Every hour of delay to surgical source control increases the odds of death (adjusted OR 1.013 per hour).
  • •De-escalate antibiotics daily based on culture results and procalcitonin kinetics. Stop antibiotics when procalcitonin falls by ≥90% from peak. Procalcitonin-guided algorithms safely reduce antibiotic duration by a mean of 1.28 days without increasing mortality.
  • •Use capillary refill time (CRT) as a resuscitation target. The ANDROMEDA-SHOCK-2 trial (2025) demonstrated superiority of CRT-targeted resuscitation (goal ≤3 seconds) over usual care (win ratio 1.16; driven by shorter vital-support duration). Do not routinely target ScvO₂ ≥70%, the PRISM meta-analysis showed no benefit.
  • •Apply lung-protective ventilation: tidal volume 6 mL/kg predicted body weight, plateau pressure <30 cm H₂O. Target SpO₂ 90-97% (conservative oxygen did not improve outcomes and may harm). Consider prone positioning if PaO₂/FiO₂ <150 mm Hg with ARDS.
  • •Delay renal replacement therapy (RRT) in septic shock with acute kidney injury unless life-threatening indications (severe hyperkalemia, acidosis, volume overload). The IDEAL-ICU trial showed no mortality benefit with early RRT; 38% of the delayed group never required RRT. Early RRT may harm patients meeting AKI by creatinine alone (58% vs 42% mortality).
  • •Provide stress ulcer prophylaxis with a proton pump inhibitor (e.g., pantoprazole 40 mg IV once daily) for mechanically ventilated patients. Administer VTE prophylaxis with low-molecular-weight heparin (e.g., enoxaparin 40 mg daily) in the absence of contraindications; maintain throughout the ICU stay.
  • •Implement the ABCDEF bundle daily: Assess-Prevent-Manage pain, Both SAT and SBT, Choice of sedation (light, non-benzodiazepine), Delirium monitoring (CAM-ICU), Early mobility (within 48 hours even on vasopressors), and Family engagement. Higher bundle adherence reduces mechanical ventilation duration and post-intensive care syndrome.
  • •Avoid harmful interventions: do not use hydroxyethyl starch (increases AKI and mortality), drotrecogin alfa (PROWESS-SHOCK: no benefit, increased bleeding), high-dose corticosteroids (>400 mg/day), tight glycemic control (80-110 mg/dL, increased hypoglycemia), or routine vitamin C (two large RCTs showed no benefit, possible harm).
  • •Refer to a high-volume ICU (≥13 septic shock cases per year) when possible; such centers have lower mortality (adjusted OR 0.63 for cancer patients). Escalate to a tertiary center when source control cannot be achieved locally, shock is refractory, or advanced organ support (e.g., ECMO) is considered.

Board Review — High Yield

  • •Sepsis-3 definition, Septic shock requires vasopressor dependence (MAP ≥65) and lactate >2 mmol/L after adequate fluid resuscitation; mortality >40%.
  • •SOFA vs qSOFA, SOFA (ICU) AUROC 0.74; qSOFA (non-ICU) AUROC 0.81 with sensitivity 65%, specificity 92%.
  • •ANDROMEDA-SHOCK-2, CRT-targeted resuscitation (goal ≤3 s) superior to usual care (win ratio 1.16); CRT is the best bedside perfusion monitor.
  • •SMART trial, Balanced crystalloids (lactated Ringer’s/PlasmaLyte) reduce 30-day mortality vs saline in sepsis (aOR 0.74; NNT=20).
  • •OPTPRESS trial, High MAP target (80-85 mm Hg) in elderly increases 90-day mortality (39.3% vs 28.6%; NNH=9); target MAP 65-70.
  • •VANISH trial, Early vasopressin reduces RRT use vs norepinephrine alone (25.4% vs 35.3%; NNT=10).
  • •APROCCHSS trial, Hydrocortisone + fludrocortisone reduces 90-day mortality in refractory shock (43% vs 49.1%; NNT=16); hydrocortisone alone (ADRENAL) does not.
  • •Source control timing, Each hour delay to surgical source control increases odds of death (aOR 1.013/h); achieve within 12 hours.
  • •IDEAL-ICU, Delayed RRT in septic AKI does not increase mortality; 38% avoid RRT entirely; early RRT may harm those with creatinine-only AKI.
  • •Abandoned therapies, Drotrecogin alfa (PROWESS-SHOCK, no benefit), HES (AKI risk), tight glycemic control (hypoglycemia), vitamin C (two negative RCTs).

Deep Dive — Evidence Details

References

  1. [1]

    Dellinger RP, Levy MM, Rhodes A et al.. “Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012.” Critical care medicine (2013). PMID: 23353941 ↗

    L1GUIDELINECited in: Definition, Classification & Shock-Physiology Spine, Epidemiology, Etiology & Risk Factors, Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation), Prevention, Screening and Post-ICU Surveillance
  2. [2]

    Rhodes A, Evans LE, Alhazzani W et al.. “Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.” Critical care medicine (2017). PMID: 28098591 ↗

    L1GUIDELINECited in: Definition, Classification & Shock-Physiology Spine, Epidemiology, Etiology & Risk Factors, Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
  3. [3]

    Rhodes A, Evans LE, Alhazzani W et al.. “Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.” Intensive care medicine (2017). PMID: 28101605 ↗

    L1GUIDELINECited in: Definition, Classification & Shock-Physiology Spine, Epidemiology, Etiology & Risk Factors, Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
  4. [4]

    Weiss SL, Peters MJ, Alhazzani W et al.. “Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children.” Intensive care medicine (2020). PMID: 32030529 ↗

    L1GUIDELINECited in: Definition, Classification & Shock-Physiology Spine, Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
  5. [5]

    Dellinger RP, Levy MM, Rhodes A et al.. “Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012.” Intensive care medicine (2013). PMID: 23361625 ↗

    L1GUIDELINECited in: Definition, Classification & Shock-Physiology Spine, Clinical Presentation, Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  6. [6]

    Annane D, Pastores SM, Rochwerg B et al.. “Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017.” Intensive care medicine (2017). PMID: 28940011 ↗

    L1GUIDELINECited in: Definition, Classification & Shock-Physiology Spine, Diagnosis & Workup (Hemodynamic & Bedside-First), History and Evolution of Treatment
  7. [7]

    Pirracchio R, Fong N, Legrand M. “Heterogeneity in the response to a high vs low mean arterial pressure target in patients with septic shock a post hoc analysis of a randomized controlled trial.” Intensive care medicine (2025). PMID: 40960603 ↗

    L2RCTCited in: Definition, Classification & Shock-Physiology Spine, Diagnosis & Workup (Hemodynamic & Bedside-First), History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  8. [8]

    Dargent A, Bourredjem A, Jacquier M et al.. “Dexmedetomidine to Reduce Vasopressor Resistance in Refractory Septic Shock: α2 Agonist Dexmedetomidine for REfractory Septic Shock (ADRESS): A Double-Blind Randomized Controlled Pilot Trial.” Critical care medicine (2025). PMID: 40019329 ↗

    L1RCTCited in: Definition, Classification & Shock-Physiology Spine, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
  9. [9]

    Coz Yataco AO, Soghier I, Hébert PC et al.. “Red Blood Cell Transfusion in Critically Ill Adults: An American College of Chest Physicians Clinical Practice Guideline.” Chest (2024). PMID: 39341492 ↗

    L1GUIDELINECited in: Definition, Classification & Shock-Physiology Spine, History and Evolution of Treatment, Complications & Iatrogenesis
  10. [10]

    Brown RM, Wang L, Coston TD et al.. “Balanced Crystalloids versus Saline in Sepsis. A Secondary Analysis of the SMART Clinical Trial.” American journal of respiratory and critical care medicine (2019). PMID: 31454263 ↗

    L2RCTCited in: Definition, Classification & Shock-Physiology Spine, Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  11. [11]

    Gaudry S, Hajage D, Schortgen F et al.. “Timing of Renal Support and Outcome of Septic Shock and Acute Respiratory Distress Syndrome. A Post Hoc Analysis of the AKIKI Randomized Clinical Trial.” American journal of respiratory and critical care medicine (2018). PMID: 29351007 ↗

    L2RCTCited in: Definition, Classification & Shock-Physiology Spine, Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
  12. [12]

    Mueller MM, Van Remoortel H, Meybohm P et al.. “Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference.” JAMA (2019). PMID: 30860564 ↗

    L1GUIDELINECited in: Definition, Classification & Shock-Physiology Spine, History and Evolution of Treatment
  13. [13]

    Menon K, Schlapbach LJ, Akech S et al.. “Criteria for Pediatric Sepsis-A Systematic Review and Meta-Analysis by the Pediatric Sepsis Definition Taskforce.” Critical care medicine (2022). PMID: 34612847 ↗

    L1SR_OBSCited in: Definition, Classification & Shock-Physiology Spine, Diagnosis & Workup (Hemodynamic & Bedside-First)
  14. [14]

    Stevenson EK, Rubenstein AR, Radin GT et al.. “Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis*.” Critical care medicine (2014). PMID: 24201173 ↗

    L1SR_OBSCited in: Definition, Classification & Shock-Physiology Spine
  15. [15]

    Sato R, Kuriyama A. “Venoarterial Extracorporeal Membranous Oxygenation: Treatment Option for Sepsis-Induced Cardiogenic Shock? A Systematic Review.” Critical care medicine (2020). PMID: 32697514 ↗

    L2SR_OBSCited in: Definition, Classification & Shock-Physiology Spine
  16. [16]

    Weiss SL, Peters MJ, Oczkowski SJW et al.. “Surviving Sepsis Campaign International Guidelines for the Management of Sepsis and Septic Shock in Children 2026.” Intensive care medicine (2026). PMID: 41870559 ↗

    L1SR_OBSCited in: Definition, Classification & Shock-Physiology Spine, Acute Resuscitation & Time-Critical Management
  17. [17]

    Pettilä V, Hjortrup PB, Jakob SM et al.. “Control groups in recent septic shock trials: a systematic review.” Intensive care medicine (2016). PMID: 27448676 ↗

    L1SR_OBSCited in: Definition, Classification & Shock-Physiology Spine, Diagnosis & Workup (Hemodynamic & Bedside-First)
  18. [18]

    Barbar SD, Clere-Jehl R, Bourredjem A et al.. “Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis.” The New England journal of medicine (2018). PMID: 30304656 ↗

    L1RCTCited in: Definition, Classification & Shock-Physiology Spine, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  19. [19]

    Fujii T, Luethi N, Young PJ et al.. “Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial.” JAMA (2020). PMID: 31950979 ↗

    L1RCTCited in: Definition, Classification & Shock-Physiology Spine, Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
  20. [20]

    Shankar-Hari M, Phillips GS, Levy ML et al.. “Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).” JAMA (2016). PMID: 26903336 ↗

    L1SR_OBSCited in: Definition, Classification & Shock-Physiology Spine, Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management
  21. [21]

    Annane D, Bellissant E, Bollaert PE et al.. “Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review.” JAMA (2009). PMID: 19509383 ↗

    L1SR_OBSCited in: Definition, Classification & Shock-Physiology Spine
  22. [22]

    Reyes LF, Garcia E, Ibáñez-Prada ED et al.. “Impact of macrolide treatment on long-term mortality in patients admitted to the ICU due to CAP: a targeted maximum likelihood estimation and survival analysis.” Critical care (London, England) (2023). PMID: 37259125 ↗

    L3RCTCited in: Definition, Classification & Shock-Physiology Spine, Definitive Therapy & Source Control of the Inciting Insult, Special Populations
  23. [23]

    Wirz Y, Meier MA, Bouadma L et al.. “Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials.” Critical care (London, England) (2018). PMID: 30111341 ↗

    L1SR_OBSCited in: Definition, Classification & Shock-Physiology Spine, Epidemiology, Etiology & Risk Factors, Severity Scoring & Risk Stratification (ICU Scores)
  24. [24]

    Vincent JL, Jones G, David S et al.. “Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis.” Critical care (London, England) (2019). PMID: 31151462 ↗

    L2SR_OBSCited in: Definition, Classification & Shock-Physiology Spine
  25. [25]

    Xu JY, Chen QH, Xie JF et al.. “Comparison of the effects of albumin and crystalloid on mortality in adult patients with severe sepsis and septic shock: a meta-analysis of randomized clinical trials.” Critical care (London, England) (2014). PMID: 25499187 ↗

    L1SR_OBSCited in: Definition, Classification & Shock-Physiology Spine
  26. [26]

    Raschke RA, Garcia-Orr R. “Hemophagocytic lymphohistiocytosis: a potentially underrecognized association with systemic inflammatory response syndrome, severe sepsis, and septic shock in adults.” Chest (2011). PMID: 21737492 ↗

    L4CASE_REPORTCited in: Definition, Classification & Shock-Physiology Spine, Diagnosis & Workup (Hemodynamic & Bedside-First)
  27. [27]

    Woolum JA, Abner EL, Kelly A et al.. “Effect of Thiamine Administration on Lactate Clearance and Mortality in Patients With Septic Shock.” Critical care medicine (2018). PMID: 30028362 ↗

    L2OTHERCited in: Definition, Classification & Shock-Physiology Spine, Diagnosis & Workup (Hemodynamic & Bedside-First)
  28. [28]

    Shen Y, Zhang W, Lin K et al.. “Blood pressure response index trajectories identify distinct hemodynamic phenotypes and predict mortality in septic shock: a two-database retrospective cohort study.” Critical care (London, England) (2026). PMID: 42057084 ↗

    L2COHORTCited in: Definition, Classification & Shock-Physiology Spine, Epidemiology, Etiology & Risk Factors, Severity Scoring & Risk Stratification (ICU Scores), Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment, Special Populations
  29. [29]

    Imaeda T, Oami T, Yokoyama T et al.. “Epidemiology and outcomes of septic shock in Japan: a nationwide retrospective cohort study from a medical claims database by the Japan Sepsis Alliance (JaSA) study group.” Critical care (London, England) (2025). PMID: 40671140 ↗

    L2COHORTCited in: Definition, Classification & Shock-Physiology Spine, Special Populations
  30. [30]

    Wong HR, Cvijanovich NZ, Anas N et al.. “Developing a clinically feasible personalized medicine approach to pediatric septic shock.” American journal of respiratory and critical care medicine (2015). PMID: 25489881 ↗

    L2OTHERCited in: Definition, Classification & Shock-Physiology Spine
  31. [31]

    Wong HR, Cvijanovich NZ, Anas N et al.. “Improved Risk Stratification in Pediatric Septic Shock Using Both Protein and mRNA Biomarkers. PERSEVERE-XP.” American journal of respiratory and critical care medicine (2017). PMID: 28324661 ↗

    L2OTHERCited in: Definition, Classification & Shock-Physiology Spine, Pathophysiology & Mechanism
  32. [32]

    Muszynski JA, Nofziger R, Moore-Clingenpeel M et al.. “Early Immune Function and Duration of Organ Dysfunction in Critically III Children with Sepsis.” American journal of respiratory and critical care medicine (2018). PMID: 29470918 ↗

    L2OTHERCited in: Definition, Classification & Shock-Physiology Spine
  33. [33]

    Weiss SL, Peters MJ, Oczkowski SJW et al.. “Surviving Sepsis Campaign International Guidelines for the Management of Sepsis and Septic Shock in Children 2026.” Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies (2026). PMID: 41869844 ↗

    L1GUIDELINECited in: Definition, Classification & Shock-Physiology Spine, Acute Resuscitation & Time-Critical Management
  34. [34]

    Scicluna BP, Cano-Gamez K, Burnham KL et al.. “A consensus blood transcriptomic framework for sepsis.” Nature medicine (2025). PMID: 41028542 ↗

    L2GUIDELINECited in: Definition, Classification & Shock-Physiology Spine, Severity Scoring & Risk Stratification (ICU Scores)
  35. [35]

    Radulescu SM, Prizeman-Green S, Seth S et al.. “Prevalence and representation of comorbidities and multimorbidity in randomised controlled trials in sepsis or septic shock: a systematic review.” Critical care (London, England) (2026). PMID: 42092974 ↗

    L1SR_MA_RCTCited in: Definition, Classification & Shock-Physiology Spine, Epidemiology, Etiology & Risk Factors
  36. [36]

    Cuenca JA, Manjappachar NK, Ramírez CM et al.. “Outcomes and Predictors of 28-Day Mortality in Patients With Solid Tumors and Septic Shock Defined by Third International Consensus Definitions for Sepsis and Septic Shock Criteria.” Chest (2022). PMID: 35644244 ↗

    L2OTHERCited in: Definition, Classification & Shock-Physiology Spine, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Hemodynamic & Bedside-First), Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  37. [37]

    Murphy CV, Schramm GE, Doherty JA et al.. “The importance of fluid management in acute lung injury secondary to septic shock.” Chest (2009). PMID: 19318675 ↗

    L2OTHERCited in: Definition, Classification & Shock-Physiology Spine
  38. [38]

    Otero RM, Nguyen HB, Huang DT et al.. “Early goal-directed therapy in severe sepsis and septic shock revisited: concepts, controversies, and contemporary findings.” Chest (2006). PMID: 17099041 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Shock-Physiology Spine, Clinical Presentation, Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management
  39. [39]

    Dugar S, Sato R, Chawla S et al.. “Is Left Ventricular Systolic Dysfunction Associated With Increased Mortality Among Patients With Sepsis and Septic Shock?” Chest (2023). PMID: 36646415 ↗

    L2OTHERCited in: Definition, Classification & Shock-Physiology Spine
  40. [40]

    Hammond NE, Kumar A, Kaur P et al.. “Estimates of Sepsis Prevalence and Outcomes in Adult Patients in the ICU in India: A Cross-sectional Study.” Chest (2022). PMID: 35092747 ↗

    L2OTHERCited in: Definition, Classification & Shock-Physiology Spine, Definitive Therapy & Source Control of the Inciting Insult
  41. [41]

    Singh G, Bhaskar V, Batra P et al.. “Dopamine versus epinephrine for neonatal septic shock: an open labeled, randomized controlled trial.” Journal of perinatology : official journal of the California Perinatal Association (2025). PMID: 40877444 ↗

    L1RCTCited in: Definition, Classification & Shock-Physiology Spine
  42. [42]

    Eaton TL, Danesh V, Jones AC et al.. “Clinician and Patient Responses to US Health Insurers' Policies: A Qualitative Study of Higher Risk Patients.” Health services research (2025). PMID: 40275640 ↗

    L5RCTCited in: Definition, Classification & Shock-Physiology Spine
  43. [43]

    Cecconi M, Evans L, Levy M et al.. “Sepsis and septic shock.” Lancet (London, England) (2018). PMID: 29937192 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Shock-Physiology Spine, Diagnosis & Workup (Hemodynamic & Bedside-First)
  44. [44]

    Singer M, Deutschman CS, Seymour CW et al.. “The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).” JAMA (2016). PMID: 26903338 ↗

    L1OTHERCited in: Definition, Classification & Shock-Physiology Spine, Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management
  45. [45]

    Schlapbach LJ, Watson RS, Sorce LR et al.. “International Consensus Criteria for Pediatric Sepsis and Septic Shock.” JAMA (2024). PMID: 38245889 ↗

    L1OTHERCited in: Definition, Classification & Shock-Physiology Spine, Diagnosis & Workup (Hemodynamic & Bedside-First)
  46. [46]

    Seymour CW, Liu VX, Iwashyna TJ et al.. “Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).” JAMA (2016). PMID: 26903335 ↗

    L2OTHERCited in: Definition, Classification & Shock-Physiology Spine, Severity Scoring & Risk Stratification (ICU Scores)
  47. [47]

    Andriolo BN, Andriolo RB, Salomão R et al.. “Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock.” The Cochrane database of systematic reviews (2017). PMID: 28099689 ↗

    L1SR_OBSCited in: Definition, Classification & Shock-Physiology Spine, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Hemodynamic & Bedside-First), Definitive Therapy & Source Control of the Inciting Insult
  48. [48]

    Corley A, Rickard CM, Aitken LM et al.. “High-flow nasal cannulae for respiratory support in adult intensive care patients.” The Cochrane database of systematic reviews (2017). PMID: 28555461 ↗

    L1SR_OBSCited in: Definition, Classification & Shock-Physiology Spine, Complications & Iatrogenesis
  49. [49]

    Lajoye Q, Orieux A, Boyer A et al.. “Vasopressin and its analogues in patients with septic shock: holy Grail or unfulfilled promise?” Critical care (London, England) (2025). PMID: 40731360 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Shock-Physiology Spine, Acute Resuscitation & Time-Critical Management
  50. [50]

    Bruno RR, Wollborn J, Fengler K et al.. “Direct assessment of microcirculation in shock: a randomized-controlled multicenter study.” Intensive care medicine (2023). PMID: 37278760 ↗

    L1RCTCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment
  51. [51]

    Cohen J, Blumenthal A, Cuellar-Partida G et al.. “The relationship between adrenocortical candidate gene expression and clinical response to hydrocortisone in patients with septic shock.” Intensive care medicine (2021). PMID: 34185116 ↗

    L2RCTCited in: Pathophysiology & Mechanism
  52. [52]

    Legrand M, Jullien E, Kimmoun A et al.. “Iloprost for the Treatment of Severe Septic Shock with Persistent Hypoperfusion: A Double-Blind, Randomized Controlled Trial.” American journal of respiratory and critical care medicine (2025). PMID: 40387381 ↗

    L1RCTCited in: Pathophysiology & Mechanism, Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  53. [53]

    Meyer NJ, Ferguson JF, Feng R et al.. “A functional synonymous coding variant in the IL1RN gene is associated with survival in septic shock.” American journal of respiratory and critical care medicine (2014). PMID: 25089931 ↗

    L2RCTCited in: Pathophysiology & Mechanism
  54. [54]

    Boerma EC, Kuiper MA, Kingma WP et al.. “Disparity between skin perfusion and sublingual microcirculatory alterations in severe sepsis and septic shock: a prospective observational study.” Intensive care medicine (2008). PMID: 18317733 ↗

    L2TRIAL_NONRANDOMCited in: Pathophysiology & Mechanism
  55. [55]

    Patel JJ, Willoughby R, Peterson J et al.. “High-Dose IV Hydroxocobalamin (Vitamin B12) in Septic Shock: A Double-Blind, Allocation-Concealed, Placebo-Controlled Single-Center Pilot Randomized Controlled Trial (The Intravenous Hydroxocobalamin in Septic Shock Trial).” Chest (2022). PMID: 36174744 ↗

    L1RCTCited in: Pathophysiology & Mechanism, Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
  56. [56]

    Biesalski HK, McGregor GP. “Antioxidant therapy in critical care--is the microcirculation the primary target?” Critical care medicine (2007). PMID: 17713412 ↗

    L5SR_OBSCited in: Pathophysiology & Mechanism
  57. [57]

    Jacquet-Lagrèze M, Pernollet A, Kattan E et al.. “Prognostic value of capillary refill time in adult patients: a systematic review with meta-analysis.” Critical care (London, England) (2023). PMID: 38042855 ↗

    L2SR_OBSCited in: Pathophysiology & Mechanism
  58. [58]

    De Backer D, Deutschman CS, Hellman J et al.. “Surviving Sepsis Campaign Research Priorities 2023.” Critical care medicine (2024). PMID: 38240508 ↗

    L5OTHERCited in: Pathophysiology & Mechanism, Acute Resuscitation & Time-Critical Management
  59. [59]

    Rudiger A. “Beta-block the septic heart.” Critical care medicine (2010). PMID: 21164404 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  60. [60]

    Sathianathan S, Sachar S, Berro J et al.. “Vasoactive Medications and the Microcirculation in Septic Shock: A Scoping Review.” Critical care medicine (2026). PMID: 41528192 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  61. [61]

    Barrett LK, Singer M, Clapp LH. “Vasopressin: mechanisms of action on the vasculature in health and in septic shock.” Critical care medicine (2007). PMID: 17133186 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  62. [62]

    Funk DJ, Jacobsohn E, Kumar A. “Role of the venous return in critical illness and shock: part II-shock and mechanical ventilation.” Critical care medicine (2013). PMID: 23263572 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  63. [63]

    Takahashi N, Campbell KR, Nakada TA et al.. “Decreased Clearance of Low-Density Lipoprotein Cholesterol is Causally Associated With Increased Mortality of Septic Shock.” Critical care medicine (2025). PMID: 40758386 ↗

    L2OTHERCited in: Pathophysiology & Mechanism
  64. [64]

    Tachon G, Harrois A, Tanaka S et al.. “Microcirculatory alterations in traumatic hemorrhagic shock.” Critical care medicine (2014). PMID: 24561562 ↗

    L2OTHERCited in: Pathophysiology & Mechanism
  65. [65]

    Fang X, Tang W, Sun S et al.. “Comparison of buccal microcirculation between septic and hemorrhagic shock.” Critical care medicine (2006). PMID: 17114976 ↗

    L5OTHERCited in: Pathophysiology & Mechanism
  66. [66]

    Russell JA. “Vasopressor therapy in critically ill patients with shock.” Intensive care medicine (2019). PMID: 31646370 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Acute Resuscitation & Time-Critical Management
  67. [67]

    Ait-Oufella H, Lemoinne S, Boelle PY et al.. “Mottling score predicts survival in septic shock.” Intensive care medicine (2011). PMID: 21373821 ↗

    L2OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup (Hemodynamic & Bedside-First), Severity Scoring & Risk Stratification (ICU Scores), Acute Resuscitation & Time-Critical Management, Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation), Special Populations
  68. [68]

    De Backer D, Cecconi M, Lipman J et al.. “Challenges in the management of septic shock: a narrative review.” Intensive care medicine (2019). PMID: 30741328 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  69. [69]

    Karvunidis T, Chvojka J, Lysak D et al.. “Septic shock and chemotherapy-induced cytopenia: effects on microcirculation.” Intensive care medicine (2012). PMID: 22584795 ↗

    L2OTHERCited in: Pathophysiology & Mechanism
  70. [70]

    Lange M, Ertmer C, Westphal M. “Vasopressin vs. terlipressin in the treatment of cardiovascular failure in sepsis.” Intensive care medicine (2007). PMID: 18066524 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  71. [71]

    Polito A, Lorin de la Grandmaison G, Mansart A et al.. “Human and experimental septic shock are characterized by depletion of lipid droplets in the adrenals.” Intensive care medicine (2010). PMID: 20665002 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  72. [72]

    Cartwright N, Murch O, McMaster SK et al.. “Selective NOD1 agonists cause shock and organ injury/dysfunction in vivo.” American journal of respiratory and critical care medicine (2007). PMID: 17234906 ↗

    L5OTHERCited in: Pathophysiology & Mechanism
  73. [73]

    Sherer K, Li Y, Cui X et al.. “Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: implications for therapy.” American journal of respiratory and critical care medicine (2006). PMID: 17095744 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  74. [74]

    Stolk RF, van der Poll T, Angus DC et al.. “Potentially Inadvertent Immunomodulation: Norepinephrine Use in Sepsis.” American journal of respiratory and critical care medicine (2016). PMID: 27398737 ↗

    L5OTHERCited in: Pathophysiology & Mechanism, Acute Resuscitation & Time-Critical Management
  75. [75]

    Maiden MJ, Otto S, Brealey JK et al.. “Structure and Function of the Kidney in Septic Shock. A Prospective Controlled Experimental Study.” American journal of respiratory and critical care medicine (2016). PMID: 26967568 ↗

    L5OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup (Hemodynamic & Bedside-First)
  76. [76]

    Kapoor A, Shintani Y, Collino M et al.. “Protective role of peroxisome proliferator-activated receptor-β/δ in septic shock.” American journal of respiratory and critical care medicine (2010). PMID: 20693380 ↗

    L5OTHERCited in: Pathophysiology & Mechanism
  77. [77]

    Wang Z, Su F, Bruhn A et al.. “Acute hypercapnia improves indices of tissue oxygenation more than dobutamine in septic shock.” American journal of respiratory and critical care medicine (2007). PMID: 17947612 ↗

    L5OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup (Hemodynamic & Bedside-First)
  78. [78]

    Chaudhuri D, Herritt B, Lewis K et al.. “Dosing Fluids in Early Septic Shock.” Chest (2020). PMID: 33058814 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management
  79. [79]

    Hollenberg SM. “Vasopressor support in septic shock.” Chest (2007). PMID: 17998371 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Acute Resuscitation & Time-Critical Management
  80. [80]

    Ferhat Y, Serkan Y, Ulaş Öİ et al.. “Peripheral Perfusion vs Standard Management in Sepsis/Septic Shock: A Prospective Randomized ED Study.” The American journal of emergency medicine (2025). PMID: 41033063 ↗

    L1RCTCited in: Pathophysiology & Mechanism, Definitive Therapy & Source Control of the Inciting Insult
  81. [81]

    Lu S, Kattan E, Pan C et al.. “VERY EARLY USE OF ESMOLOL IN HYPERKINETIC SEPTIC SHOCK PATIENTS WITH PERSISTENT TACHYCARDIA: A RANDOMIZED CONTROLLED PILOT STUDY.” Shock (Augusta, Ga.) (2025). PMID: 40101954 ↗

    L1RCTCited in: Pathophysiology & Mechanism, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  82. [82]

    Cusack RAF, Rodríguez A, Cantan B et al.. “Microcirculation properties of 20 % albumin in sepsis; a randomised controlled trial.” Journal of critical care (2025). PMID: 40020556 ↗

    L1RCTCited in: Pathophysiology & Mechanism
  83. [83]

    Luo JC, Ma L, Luo MH et al.. “Early Methylene Blue for Mortality Reduction in High-Dose VasoPREssor-Dependent Septic Shock (EMPRESS): protocol for a multicenter randomized controlled trial.” Scandinavian journal of trauma, resuscitation and emergency medicine (2026). PMID: 41580807 ↗

    L5TRIAL_NONRANDOMCited in: Pathophysiology & Mechanism, Acute Resuscitation & Time-Critical Management
  84. [84]

    Vignon P, Léger J, Evrard B et al.. “Adjunctive dobutamine in patients with septic cardiomyopathy and tissue hypoperfusion: a blinded randomised controlled multicentre trial study protocol of the ADAPT-dobutamine trial.” BMJ open (2025). PMID: 40588393 ↗

    L5TRIAL_NONRANDOMCited in: Pathophysiology & Mechanism
  85. [85]

    Christensen J, Sivapalan P, Meyhoff TS et al.. “Restrictive Versus Standard Intravenous Fluid Therapy and Endothelial Glycocalyx Shedding in ICU Patients With Septic Shock-A Preplanned Sub-Study of the Randomized CLASSIC Trial.” Acta anaesthesiologica Scandinavica (2026). PMID: 41321198 ↗

    L1RCTCited in: Pathophysiology & Mechanism
  86. [86]

    Calabrò LA, Pasetto M, Scolletta S et al.. “Ivabradine use in critical care: a systematic review and metanalysis of cardiogenic and septic shock patients.” BMC anesthesiology (2025). PMID: 40448257 ↗

    L5SR_OBSCited in: Pathophysiology & Mechanism
  87. [87]

    Zhang X, Zhang H, Jin R et al.. “Assessment of Sublingual Microcirculation to Evaluate the Efficacy of Resuscitation Therapy in Septic Shock Patients: A Cohort Study.” Shock (Augusta, Ga.) (2025). PMID: 41031817 ↗

    L2COHORTCited in: Pathophysiology & Mechanism
  88. [88]

    Lambden S, Creagh-Brown BC, Hunt J et al.. “Definitions and pathophysiology of vasoplegic shock.” Critical care (London, England) (2018). PMID: 29980217 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  89. [89]

    Kellum JA, Ronco C. “The role of endotoxin in septic shock.” Critical care (London, England) (2023). PMID: 37858258 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup (Hemodynamic & Bedside-First)
  90. [90]

    Levy B, Fritz C, Tahon E et al.. “Vasoplegia treatments: the past, the present, and the future.” Critical care (London, England) (2018). PMID: 29486781 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Acute Resuscitation & Time-Critical Management
  91. [91]

    Atreya MR, Huang M, Moore AR et al.. “Identification and transcriptomic assessment of latent profile pediatric septic shock phenotypes.” Critical care (London, England) (2024). PMID: 39014377 ↗

    L2OTHERCited in: Pathophysiology & Mechanism
  92. [92]

    Atreya MR, Cvijanovich NZ, Fitzgerald JC et al.. “Prognostic and predictive value of endothelial dysfunction biomarkers in sepsis-associated acute kidney injury: risk-stratified analysis from a prospective observational cohort of pediatric septic shock.” Critical care (London, England) (2023). PMID: 37400882 ↗

    L2OTHERCited in: Pathophysiology & Mechanism
  93. [93]

    Garcia B, Su F, Manicone F et al.. “Angiotensin 1-7 in an experimental septic shock model.” Critical care (London, England) (2023). PMID: 36915144 ↗

    L5OTHERCited in: Pathophysiology & Mechanism
  94. [94]

    Ronco C, Klein DJ. “Polymyxin B hemoperfusion: a mechanistic perspective.” Critical care (London, England) (2014). PMID: 25043934 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  95. [95]

    Picod A, Azibani F, Harjola VP et al.. “Targeting high circulating dipeptidyl peptidase 3 in circulatory failure.” Critical care (London, England) (2025). PMID: 40745610 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  96. [96]

    Chen JJ, Lai PC, Lee TH et al.. “Blood Purification for Adult Patients With Severe Infection or Sepsis/Septic Shock: A Network Meta-Analysis of Randomized Controlled Trials.” Critical care medicine (2023). PMID: 37470680 ↗

    L1SR_MA_RCTCited in: Epidemiology, Etiology & Risk Factors, Special Populations
  97. [97]

    Pettilä V, Pfortmüller CA, Perner A et al.. “Targeted Tissue Perfusion Versus Macrocirculatory-Guided Standard Care in Patients With Septic Shock: A Randomized Clinical Trial-The TARTARE-2S Trial.” Critical care medicine (2025). PMID: 41105050 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
  98. [98]

    Monti G, Carta S, Kotani Y et al.. “A Multinational Randomized Trial of Mega-Dose Esomeprazole as Anti-Inflammatory Agent in Sepsis.” Critical care medicine (2025). PMID: 40439536 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity Scoring & Risk Stratification (ICU Scores), Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Special Populations
  99. [99]

    Shah S, Kaul A, Shiwarkar G et al.. “Fifth Centile Versus 50th Centile Mean Blood Pressure Targets in Pediatric Septic Shock: A Randomized Controlled Trial.” Critical care medicine (2025). PMID: 40511998 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  100. [100]

    Endo A, Yamakawa K, Tagami T et al.. “Efficacy of targeting high mean arterial pressure for older patients with septic shock (OPTPRESS): a multicentre, pragmatic, open-label, randomised controlled trial.” Intensive care medicine (2025). PMID: 40358717 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Resuscitation & Time-Critical Management, Special Populations
  101. [101]

    Myburgh JA, Higgins A, Jovanovska A et al.. “A comparison of epinephrine and norepinephrine in critically ill patients.” Intensive care medicine (2008). PMID: 18654759 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
  102. [102]

    Walsham J, Hammond N, Blumenthal A et al.. “Fludrocortisone dose-response relationship in septic shock: a randomised phase II trial.” Intensive care medicine (2024). PMID: 39235623 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Special Populations
  103. [103]

    Shehabi Y, Sterba M, Garrett PM et al.. “Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial.” American journal of respiratory and critical care medicine (2014). PMID: 25295709 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, Special Populations
  104. [104]

    Nobre V, Harbarth S, Graf JD et al.. “Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial.” American journal of respiratory and critical care medicine (2007). PMID: 18096708 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, Special Populations
  105. [105]

    Schmidt EP, Overdier KH, Sun X et al.. “Urinary Glycosaminoglycans Predict Outcomes in Septic Shock and Acute Respiratory Distress Syndrome.” American journal of respiratory and critical care medicine (2016). PMID: 26926297 ↗

    L2TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Severity Scoring & Risk Stratification (ICU Scores), Special Populations
  106. [106]

    Peake SL, Delaney A, Bailey M et al.. “Goal-directed resuscitation for patients with early septic shock.” The New England journal of medicine (2014). PMID: 25272316 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Special Populations
  107. [107]

    Holst LB, Haase N, Wetterslev J et al.. “Lower versus higher hemoglobin threshold for transfusion in septic shock.” The New England journal of medicine (2014). PMID: 25270275 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, Special Populations
  108. [108]

    Hernández G, Ospina-Tascón GA, Damiani LP et al.. “Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients With Septic Shock: The ANDROMEDA-SHOCK Randomized Clinical Trial.” JAMA (2019). PMID: 30772908 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Hemodynamic & Bedside-First), Severity Scoring & Risk Stratification (ICU Scores), Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
  109. [109]

    Gordon AC, Mason AJ, Thirunavukkarasu N et al.. “Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial.” JAMA (2016). PMID: 27483065 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Complications & Iatrogenesis, Special Populations
  110. [110]

    Morelli A, Ertmer C, Westphal M et al.. “Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial.” JAMA (2013). PMID: 24108526 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
  111. [111]

    Keh D, Trips E, Marx G et al.. “Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis: The HYPRESS Randomized Clinical Trial.” JAMA (2016). PMID: 27695824 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS), Special Populations
  112. [112]

    Schmidt K, Worrack S, Von Korff M et al.. “Effect of a Primary Care Management Intervention on Mental Health-Related Quality of Life Among Survivors of Sepsis: A Randomized Clinical Trial.” JAMA (2016). PMID: 27367877 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
  113. [113]

    Blot S, Antonelli M, Arvaniti K et al.. “Epidemiology of intra-abdominal infection and sepsis in critically ill patients: "AbSeS", a multinational observational cohort study and ESICM Trials Group Project.” Intensive care medicine (2019). PMID: 31664501 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, Special Populations
  114. [114]

    Martin-Loeches I, Reyes LF, Nseir S et al.. “European Network for ICU-Related Respiratory Infections (ENIRRIs): a multinational, prospective, cohort study of nosocomial LRTI.” Intensive care medicine (2023). PMID: 37812242 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, Complications & Iatrogenesis
  115. [115]

    Klein Klouwenberg PM, Frencken JF, Kuipers S et al.. “Incidence, Predictors, and Outcomes of New-Onset Atrial Fibrillation in Critically Ill Patients with Sepsis. A Cohort Study.” American journal of respiratory and critical care medicine (2017). PMID: 27467907 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Special Populations
  116. [116]

    Abdul-Aziz MH, Hammond NE, Brett SJ et al.. “Prolonged vs Intermittent Infusions of β-Lactam Antibiotics in Adults With Sepsis or Septic Shock: A Systematic Review and Meta-Analysis.” JAMA (2024). PMID: 38864162 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  117. [117]

    Ortiz-Reyes L, Patel JJ, Jiang X et al.. “Early versus delayed enteral nutrition in mechanically ventilated patients with circulatory shock: a nested cohort analysis of an international multicenter, pragmatic clinical trial.” Critical care (London, England) (2022). PMID: 35681220 ↗

    L2RCTCited in: Epidemiology, Etiology & Risk Factors, Severity Scoring & Risk Stratification (ICU Scores), Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  118. [118]

    Vandervelden S, Cortens B, Fieuws S et al.. “Early administration of vitamin C in patients with sepsis or septic shock in emergency departments: a multicenter, double-blind, randomized controlled trial: the C-EASIE trial.” Critical care (London, England) (2025). PMID: 40269974 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity Scoring & Risk Stratification (ICU Scores), Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
  119. [119]

    Boulet N, Quenot JP, Serrand C et al.. “Impact on fluid balance of an optimized restrictive strategy targeting non-resuscitative fluids in intensive care patients with septic shock: a single-blind, multicenter, randomized, controlled, pilot study.” Critical care (London, England) (2024). PMID: 39709493 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
  120. [120]

    Roggeveen LF, Guo T, Fleuren LM et al.. “Right dose, right now: bedside, real-time, data-driven, and personalised antibiotic dosing in critically ill patients with sepsis or septic shock-a two-centre randomised clinical trial.” Critical care (London, England) (2022). PMID: 36064438 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Hemodynamic & Bedside-First), Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment
  121. [121]

    Chappell MC, Schaich CL, Busse LW et al.. “Stronger association of intact angiotensinogen with mortality than lactate or renin in critical illness: post-hoc analysis from the VICTAS trial.” Critical care (London, England) (2024). PMID: 39402593 ↗

    L2RCTCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation), Special Populations
  122. [122]

    Shi R, Braïk R, Monnet X et al.. “Early norepinephrine for patients with septic shock: an updated systematic review and meta-analysis with trial sequential analysis.” Critical care (London, England) (2025). PMID: 40329359 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management
  123. [123]

    Xie J, Wang H, Kang Y et al.. “The Epidemiology of Sepsis in Chinese ICUs: A National Cross-Sectional Survey.” Critical care medicine (2020). PMID: 31804299 ↗

    L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Hemodynamic & Bedside-First), Special Populations
  124. [124]

    Leligdowicz A, Dodek PM, Norena M et al.. “Association between source of infection and hospital mortality in patients who have septic shock.” American journal of respiratory and critical care medicine (2014). PMID: 24635548 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Hemodynamic & Bedside-First), Special Populations
  125. [125]

    Miller RR, Dong L, Nelson NC et al.. “Multicenter implementation of a severe sepsis and septic shock treatment bundle.” American journal of respiratory and critical care medicine (2013). PMID: 23631750 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity Scoring & Risk Stratification (ICU Scores), Special Populations
  126. [126]

    Mickiewicz B, Vogel HJ, Wong HR et al.. “Metabolomics as a novel approach for early diagnosis of pediatric septic shock and its mortality.” American journal of respiratory and critical care medicine (2013). PMID: 23471468 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Hemodynamic & Bedside-First), Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  127. [127]

    Lac J, Han S, Ahmad M et al.. “Low-dose corticosteroids in severe pulmonary infection: a meta-analysis of randomised controlled trials.” BMJ open respiratory research (2026). PMID: 42425738 ↗

    L1SR_MA_RCTCited in: Epidemiology, Etiology & Risk Factors
  128. [128]

    Nguyen N, Tran NB, de Barros E Lyra NA et al.. “Conservative Oxygen Targets in Mechanically Ventilated Patients (OXY-BREATHES): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Critical care medicine (2026). PMID: 41661051 ↗

    L1SR_MA_RCTCited in: Epidemiology, Etiology & Risk Factors
  129. [129]

    Lanspa MJ, Cirulis MM, Wiley BM et al.. “Right Ventricular Dysfunction in Early Sepsis and Septic Shock.” Chest (2020). PMID: 33068615 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Hemodynamic & Bedside-First), Severity Scoring & Risk Stratification (ICU Scores), Acute Resuscitation & Time-Critical Management
  130. [130]

    Marik PE, Khangoora V, Rivera R et al.. “Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study.” Chest (2016). PMID: 27940189 ↗

    L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Acute Resuscitation & Time-Critical Management, Special Populations
  131. [131]

    John S, Eckardt KU. “Renal replacement strategies in the ICU.” Chest (2007). PMID: 17934125 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Special Populations
  132. [132]

    Canet E, Zafrani L, Azoulay É. “The Critically Ill Kidney Transplant Recipient: A Narrative Review.” Chest (2016). PMID: 26836919 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
  133. [133]

    Chockalingam A, Mehra A, Dorairajan S et al.. “Acute left ventricular dysfunction in the critically ill.” Chest (2010). PMID: 20605820 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Hemodynamic & Bedside-First), Definitive Therapy & Source Control of the Inciting Insult, Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  134. [134]

    Grasselli G, Scaravilli V, Mangioni D et al.. “Hospital-Acquired Infections in Critically Ill Patients With COVID-19.” Chest (2021). PMID: 33857475 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications & Iatrogenesis, Special Populations
  135. [135]

    Serrano-Mayorga CC, Olivella-Gomez J, Sanabria-Herrera N et al.. “Pseudomonas aeruginosa in Patients With Nosocomial Respiratory Infections: A Secondary Analysis of the European Network for ICU-Related Respiratory Infections.” Chest (2026). PMID: 41520818 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, Complications & Iatrogenesis, Special Populations
  136. [136]

    Sakr Y, Nierhaus A, Schumacher U et al.. “Albumin Replacement Therapy in Septic Shock: A Randomized Clinical Trial.” JAMA network open (2026). PMID: 41712212 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, Special Populations
  137. [137]

    Meng L, Liu J, Wang P et al.. “Risk factors of sepsis-associated encephalopathy in sepsis patients with pulmonary infection: from the secondary analysis of a cluster-randomized controlled trial.” Respiratory medicine (2026). PMID: 41570945 ↗

    L2RCTCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation), Special Populations
  138. [138]

    Kalimouttou A, Kennedy JN, Feng J et al.. “Optimal Vasopressin Initiation in Septic Shock: The OVISS Reinforcement Learning Study.” JAMA (2025). PMID: 40098600 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity Scoring & Risk Stratification (ICU Scores), Acute Resuscitation & Time-Critical Management, Special Populations
  139. [139]

    Zampieri FG, Bagshaw SM, Semler MW. “Fluid Therapy for Critically Ill Adults With Sepsis: A Review.” JAMA (2023). PMID: 37314271 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management
  140. [140]

    Fu Y, Wang T, Lu R et al.. “Red blood cell transfusion in neurocritical patients: an updated systematic review and meta-analysis.” BMC anesthesiology (2026). PMID: 41918075 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  141. [141]

    Guvenc KB, Sahin EG, Yılmaz IA et al.. “Early hematologic cellular effects of IgM-enriched intravenous immunoglobulin in pediatric sepsis: a retrospective cohort study.” European journal of pediatrics (2026). PMID: 41984212 ↗

    L4COHORTCited in: Epidemiology, Etiology & Risk Factors
  142. [142]

    Borthwick EM, Hill CJ, Rabindranath KS et al.. “High-volume haemofiltration for sepsis in adults.” The Cochrane database of systematic reviews (2017). PMID: 28141912 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  143. [143]

    Borthwick EM, Hill CJ, Rabindranath KS et al.. “High-volume haemofiltration for sepsis.” The Cochrane database of systematic reviews (2013). PMID: 23440825 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult
  144. [144]

    Bruder EA, Ball IM, Ridi S et al.. “Single induction dose of etomidate versus other induction agents for endotracheal intubation in critically ill patients.” The Cochrane database of systematic reviews (2015). PMID: 25568981 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity Scoring & Risk Stratification (ICU Scores)
  145. [145]

    Delgado Moya FP, Antequera A, Muriel A et al.. “Buffered solutions versus 0.9% saline for resuscitation in critically ill adults and children.” The Cochrane database of systematic reviews (2026). PMID: 42011817 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  146. [146]

    Rivers EP, Kruse JA, Jacobsen G et al.. “The influence of early hemodynamic optimization on biomarker patterns of severe sepsis and septic shock.” Critical care medicine (2007). PMID: 17855815 ↗

    L1RCTCited in: Clinical Presentation
  147. [147]

    Contou D, Sonneville R, Canoui-Poitrine F et al.. “Clinical spectrum and short-term outcome of adult patients with purpura fulminans: a French multicenter retrospective cohort study.” Intensive care medicine (2018). PMID: 30128591 ↗

    L2COHORTCited in: Clinical Presentation
  148. [148]

    Saiyed A, Datta D. “A Middle-Aged Woman With Hematochezia, Hypotension, and Leg Cramps.” Chest (2020). PMID: 32654734 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  149. [149]

    Dellinger RP, Levy MM, Carlet JM et al.. “Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.” Critical care medicine (2008). PMID: 18158437 ↗

    L1OTHERCited in: Clinical Presentation
  150. [150]

    Yang Y, Guo F, Zhao W et al.. “Novel avian-origin influenza A (H7N9) in critically ill patients in China*.” Critical care medicine (2015). PMID: 25365721 ↗

    L2OTHERCited in: Clinical Presentation
  151. [151]

    Wong HR, Cvijanovich N, Allen GL et al.. “Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum.” Critical care medicine (2009). PMID: 19325468 ↗

    L2OTHERCited in: Clinical Presentation
  152. [152]

    Boyd JH, Forbes J, Nakada TA et al.. “Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality.” Critical care medicine (2011). PMID: 20975548 ↗

    L3OTHERCited in: Clinical Presentation
  153. [153]

    Capp R, Horton CL, Takhar SS et al.. “Predictors of patients who present to the emergency department with sepsis and progress to septic shock between 4 and 48 hours of emergency department arrival.” Critical care medicine (2015). PMID: 25668750 ↗

    L3OTHERCited in: Clinical Presentation
  154. [154]

    Deep A, Sagar H, Goonasekera C et al.. “Evolution of Acute Kidney Injury and Its Association With Systemic Hemodynamics in Children With Fluid-Refractory Septic Shock.” Critical care medicine (2018). PMID: 29677008 ↗

    L2OTHERCited in: Clinical Presentation
  155. [155]

    Merdji H, Long MT, Ostermann M et al.. “Sex and gender differences in intensive care medicine.” Intensive care medicine (2023). PMID: 37676504 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS), Prevention, Screening and Post-ICU Surveillance
  156. [156]

    Deep A, Goonasekera CD, Wang Y et al.. “Evolution of haemodynamics and outcome of fluid-refractory septic shock in children.” Intensive care medicine (2013). PMID: 23812341 ↗

    L2OTHERCited in: Clinical Presentation
  157. [157]

    Bassetti M, Peghin M, Carnelutti A et al.. “Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study.” Intensive care medicine (2017). PMID: 28271321 ↗

    L3OTHERCited in: Clinical Presentation, Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  158. [158]

    Dellinger RP, Levy MM, Carlet JM et al.. “Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.” Intensive care medicine (2007). PMID: 18058085 ↗

    L1OTHERCited in: Clinical Presentation
  159. [159]

    Bisarya R, Song X, Salle J et al.. “Antibiotic Timing and Progression to Septic Shock Among Patients in the ED With Suspected Infection.” Chest (2021). PMID: 34186038 ↗

    L3OTHERCited in: Clinical Presentation
  160. [160]

    Dremsizov T, Clermont G, Kellum JA et al.. “Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course?” Chest (2006). PMID: 16608946 ↗

    L3OTHERCited in: Clinical Presentation
  161. [161]

    Self WH, Grijalva CG, Williams DJ et al.. “Procalcitonin as an Early Marker of the Need for Invasive Respiratory or Vasopressor Support in Adults With Community-Acquired Pneumonia.” Chest (2016). PMID: 27107491 ↗

    L2OTHERCited in: Clinical Presentation
  162. [162]

    Seymour CW, Rosengart MR. “Septic Shock: Advances in Diagnosis and Treatment.” JAMA (2015). PMID: 26284722 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup (Hemodynamic & Bedside-First)
  163. [163]

    Dong J, Ouyang Y, Ni J et al.. “Development and internal validation of a clinical prediction model for septic shock in pediatric respiratory syncytial virus bronchiolitis based on routine blood biomarkers and concomitant fungal infection.” Frontiers in cellular and infection microbiology (2026). PMID: 42221582 ↗

    L3TRIAL_NONRANDOMCited in: Clinical Presentation, Severity Scoring & Risk Stratification (ICU Scores)
  164. [164]

    Weiss SL, Fitzgerald JC, Laskin BL et al.. “Time Course of Kidney Injury Biomarkers in Children With Septic Shock: Nested Cohort Study Within the Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis Trial.” Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies (2025). PMID: 40172287 ↗

    L2TRIAL_NONRANDOMCited in: Clinical Presentation
  165. [165]

    Imamura M, Duggan SN, Vadiveloo T et al.. “Clinical utility of biomarkers for outcomes prediction in adults with suspected sepsis presenting to the emergency department: a synthesis of current evidence.” Health technology assessment (Winchester, England) (2026). PMID: 41912331 ↗

    L5SR_OBSCited in: Clinical Presentation
  166. [166]

    Jung RG, Gupta A, Stotts C et al.. “Prognostic factors associated with mortality in septic shock: a systematic review and meta-analysis.” The Lancet. Respiratory medicine (2026). PMID: 41619747 ↗

    L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup (Hemodynamic & Bedside-First)
  167. [167]

    Guarino M, Maroncelli G, Perna B et al.. “Comparison of four noninvasive tools for predicting sepsis and septic shock mortality: a prospective cohort study.” Clinical and experimental emergency medicine (2025). PMID: 41327979 ↗

    L2COHORTCited in: Clinical Presentation
  168. [168]

    Coston TD, Wright SW, Hantrakun V et al.. “Pre-Referral Antibiotics and Mortality Among Adults With Sepsis in Southeast Asia: A Secondary Analysis of a Prospective Cohort Study.” Critical care medicine (2025). PMID: 41196125 ↗

    L2COHORTCited in: Clinical Presentation
  169. [169]

    Bavaro DF, Diella L, De Angelis A et al.. “Why do echinocandins fail? Identifying key predictors to improve clinical outcomes of candida bloodstream infections: a retrospective multicenter cohort study.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2025). PMID: 40912531 ↗

    L3COHORTCited in: Clinical Presentation
  170. [170]

    Siddiqui S, Razzak J. “Early versus late pre-intensive care unit admission broad spectrum antibiotics for severe sepsis in adults.” The Cochrane database of systematic reviews (2010). PMID: 20927754 ↗

    L1SR_OBSCited in: Clinical Presentation
  171. [171]

    . “36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016.” Critical care (London, England) (2016). PMID: 27885969 ↗

    L5OTHERCited in: Clinical Presentation
  172. [172]

    Leligdowicz A, Fischer WA, Uyeki TM et al.. “Ebola virus disease and critical illness.” Critical care (London, England) (2016). PMID: 27468829 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  173. [173]

    Ho BC, Bellomo R, McGain F et al.. “The incidence and outcome of septic shock patients in the absence of early-goal directed therapy.” Critical care (London, England) (2006). PMID: 16704743 ↗

    L3OTHERCited in: Clinical Presentation
  174. [174]

    Rivers E. “The outcome of patients presenting to the emergency department with severe sepsis or septic shock.” Critical care (London, England) (2006). PMID: 16887012 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  175. [175]

    Yang JO, Zinter MS, Pellegrini M et al.. “Whole blood transcriptomics identifies subclasses of pediatric septic shock.” Critical care (London, England) (2023). PMID: 38066613 ↗

    L2OTHERCited in: Clinical Presentation
  176. [176]

    Marik PE. “Don't miss the diagnosis of sepsis!” Critical care (London, England) (2014). PMID: 25675360 ↗

    L5OTHERCited in: Clinical Presentation
  177. [177]

    Giamarellos-Bourboulis EJ, Routsi C, Plachouras D et al.. “Early apoptosis of blood monocytes in the septic host: is it a mechanism of protection in the event of septic shock?” Critical care (London, England) (2006). PMID: 16696867 ↗

    L2OTHERCited in: Clinical Presentation
  178. [178]

    Nagendran M, Russell JA, Walley KR et al.. “Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials.” Intensive care medicine (2019). PMID: 31062052 ↗

    L1SR_MA_RCTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
  179. [179]

    Almeida TML, Freitas FGR, Figueiredo RC et al.. “Acetylsalicylic Acid Treatment in Patients With Sepsis and Septic Shock: A Phase 2, Placebo-Controlled, Randomized Clinical Trial.” Critical care medicine (2025). PMID: 39982179 ↗

    L1RCTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Severity Scoring & Risk Stratification (ICU Scores), Definitive Therapy & Source Control of the Inciting Insult, Special Populations
  180. [180]

    Permpikul C, Tongyoo S, Viarasilpa T et al.. “Early Use of Norepinephrine in Septic Shock Resuscitation (CENSER). A Randomized Trial.” American journal of respiratory and critical care medicine (2019). PMID: 30704260 ↗

    L1RCTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
  181. [181]

    Delabranche X, Boisramé-Helms J, Asfar P et al.. “Microparticles are new biomarkers of septic shock-induced disseminated intravascular coagulopathy.” Intensive care medicine (2013). PMID: 23793890 ↗

    L2TRIAL_NONRANDOMCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
  182. [182]

    Hou PC, Filbin MR, Wang H et al.. “Endothelial Permeability and Hemostasis in Septic Shock: Results From the ProCESS Trial.” Chest (2017). PMID: 28109962 ↗

    L2RCTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), History and Evolution of Treatment
  183. [183]

    Uzzan B, Cohen R, Nicolas P et al.. “Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis.” Critical care medicine (2006). PMID: 16715031 ↗

    L1SR_OBSCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
  184. [184]

    Shankar-Hari M, Culshaw N, Post B et al.. “Endogenous IgG hypogammaglobulinaemia in critically ill adults with sepsis: systematic review and meta-analysis.” Intensive care medicine (2015). PMID: 25971390 ↗

    L1SR_OBSCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
  185. [185]

    Brunkhorst FM, Engel C, Bloos F et al.. “Intensive insulin therapy and pentastarch resuscitation in severe sepsis.” The New England journal of medicine (2008). PMID: 18184958 ↗

    L1RCTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Definitive Therapy & Source Control of the Inciting Insult, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
  186. [186]

    Hernandez G, Ospina-Tascón GA, Kattan E et al.. “Personalized Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock: The ANDROMEDA-SHOCK-2 Randomized Clinical Trial.” JAMA (2025). PMID: 41159835 ↗

    L1RCTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  187. [187]

    Jones AE, Shapiro NI, Trzeciak S et al.. “Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial.” JAMA (2010). PMID: 20179283 ↗

    L1RCTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  188. [188]

    Fernando SM, Rochwerg B, Soliman K et al.. “Methylene Blue Administration in Septic Shock: A Retrospective Cohort Study.” Critical care medicine (2025). PMID: 41171046 ↗

    L2COHORTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
  189. [189]

    Rowan KM, Angus DC, Bailey M et al.. “Early, Goal-Directed Therapy for Septic Shock - A Patient-Level Meta-Analysis.” The New England journal of medicine (2017). PMID: 28320242 ↗

    L1SR_OBSCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management
  190. [190]

    Bréchot N, Hajage D, Kimmoun A et al.. “Venoarterial extracorporeal membrane oxygenation to rescue sepsis-induced cardiogenic shock: a retrospective, multicentre, international cohort study.” Lancet (London, England) (2020). PMID: 32828186 ↗

    L2COHORTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
  191. [191]

    Yanase F, Spano S, Maeda A et al.. “Mega-dose sodium ascorbate: a pilot, single-dose, physiological effect, double-blind, randomized, controlled trial.” Critical care (London, England) (2023). PMID: 37828547 ↗

    L1RCTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), History and Evolution of Treatment
  192. [192]

    Lamarche-Fontaneto R, Oud L, Howell KD et al.. “Cardiac output monitors in septic shock: do they deliver what matters? A systematic review and meta-analysis.” Critical care (London, England) (2025). PMID: 40652247 ↗

    L1SR_OBSCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
  193. [193]

    Sacha GL, Lam SW, Wang L et al.. “Association of Catecholamine Dose, Lactate, and Shock Duration at Vasopressin Initiation With Mortality in Patients With Septic Shock.” Critical care medicine (2022). PMID: 34582425 ↗

    L2OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management
  194. [194]

    Leone M, Myatra SN, Dugar S et al.. “Clinical Criteria for the Definition of Refractory Septic Shock: A Joint Delphi Consensus from the Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM).” Critical care medicine (2026). PMID: 41873857 ↗

    L5OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
  195. [195]

    Delaney A, Borges-Sa M, Chew MS et al.. “Current standard of care for septic shock.” Intensive care medicine (2025). PMID: 41359028 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management
  196. [196]

    Zampieri FG, Damiani LP, Bakker J et al.. “Effects of a Resuscitation Strategy Targeting Peripheral Perfusion Status versus Serum Lactate Levels among Patients with Septic Shock. A Bayesian Reanalysis of the ANDROMEDA-SHOCK Trial.” American journal of respiratory and critical care medicine (2020). PMID: 31574228 ↗

    L2OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management
  197. [197]

    Annane D, Maxime V, Ibrahim F et al.. “Diagnosis of adrenal insufficiency in severe sepsis and septic shock.” American journal of respiratory and critical care medicine (2006). PMID: 16973979 ↗

    L2OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
  198. [198]

    Dépret F, Hollinger A, Cariou A et al.. “Incidence and Outcome of Subclinical Acute Kidney Injury Using penKid in Critically Ill Patients.” American journal of respiratory and critical care medicine (2020). PMID: 32516543 ↗

    L2OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
  199. [199]

    Wong HR, Cvijanovich N, Wheeler DS et al.. “Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock.” American journal of respiratory and critical care medicine (2008). PMID: 18511707 ↗

    L2OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
  200. [200]

    Lichtenstein DA. “BLUE-protocol and FALLS-protocol: two applications of lung ultrasound in the critically ill.” Chest (2015). PMID: 26033127 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
  201. [201]

    Sacha GL, Bauer SR. “Optimizing Vasopressin Use and Initiation Timing in Septic Shock: A Narrative Review.” Chest (2023). PMID: 37479058 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management
  202. [202]

    Kethireddy S, Light RB, Mirzanejad Y et al.. “Mycobacterium tuberculosis septic shock.” Chest (2013). PMID: 23429859 ↗

    L3OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
  203. [203]

    Seymour CW, Gesten F, Prescott HC et al.. “Time to Treatment and Mortality during Mandated Emergency Care for Sepsis.” The New England journal of medicine (2017). PMID: 28528569 ↗

    L3OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management
  204. [204]

    Sanchez-Pinto LN, Bennett TD, DeWitt PE et al.. “Development and Validation of the Phoenix Criteria for Pediatric Sepsis and Septic Shock.” JAMA (2024). PMID: 38245897 ↗

    L3OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
  205. [205]

    Ghatak T, Pal A, Rochwerg B et al.. “The diagnostic accuracy of serum procalcitonin for sepsis in critically ill adults. A systematic review and diagnostic meta-analysis.” Journal of critical care (2025). PMID: 41421176 ↗

    L1SR_OBSCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
  206. [206]

    Wang Y, Chen G, Zhai N et al.. “Risk factors for 28-day mortality and pathogen characteristics of septic shock in children: a 10-year retrospective cohort study.” Frontiers in cellular and infection microbiology (2026). PMID: 42256218 ↗

    L3COHORTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Complications & Iatrogenesis
  207. [207]

    Choi JW, Shin TG, Maeng SJ et al.. “Effect of norepinephrine initiation timing on mortality in septic shock: a multicenter cohort study.” BMC anesthesiology (2026). PMID: 41549241 ↗

    L3COHORTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
  208. [208]

    Liao D, Zhang S, Zhang J et al.. “Association of the Lactate-to-Albumin Ratio With All-Cause Mortality in Trauma and Surgical Intensive Care Patients: A Retrospective Study.” The Journal of surgical research (2025). PMID: 41411770 ↗

    L3COHORTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  209. [209]

    Kuriyama A, Heels-Ansdell D, Fernando SM et al.. “Pantoprazole Use in Invasively Ventilated Patients With Septic Shock: A Protocol and Statistical Analysis Plan.” Acta anaesthesiologica Scandinavica (2026). PMID: 42186360 ↗

    L5TRIAL_NONRANDOMCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Prevention, Screening and Post-ICU Surveillance
  210. [210]

    De Backer D, Cecconi M, Chew MS et al.. “A plea for personalization of the hemodynamic management of septic shock.” Critical care (London, England) (2022). PMID: 36457089 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
  211. [211]

    Barichello T, Generoso JS, Singer M et al.. “Biomarkers for sepsis: more than just fever and leukocytosis-a narrative review.” Critical care (London, England) (2022). PMID: 34991675 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
  212. [212]

    Nates JL, Pène F, Darmon M et al.. “Septic shock in the immunocompromised cancer patient: a narrative review.” Critical care (London, England) (2024). PMID: 39215292 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
  213. [213]

    Monnet X, Lai C, Ospina-Tascon G et al.. “Evidence for a personalized early start of norepinephrine in septic shock.” Critical care (London, England) (2023). PMID: 37608327 ↗

    L5OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
  214. [214]

    White KC, Costa-Pinto R, Blank S et al.. “Effect of early adjunctive vasopressin initiation for septic shock patients: a target trial emulation.” Critical care (London, England) (2025). PMID: 40355911 ↗

    L3OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Severity Scoring & Risk Stratification (ICU Scores), Acute Resuscitation & Time-Critical Management
  215. [215]

    Jiang H, Xie Z, Xiang J et al.. “Diagnostic Value of End-Tidal Carbon Dioxide Combined With Lactate for Early Detection of Sepsis in Prehospital Patients: A Prospective Cohort Study.” Medical science monitor : international medical journal of experimental and clinical research (2026). PMID: 41973647 ↗

    L2COHORTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
  216. [216]

    Jacq E, Maire F, Cucherousset J et al.. “From Cutaneous Necrosis to Septic Shock: An ICU Case of Pancreatico portal Fistula Complicating Necrotizing Acute Pancreatitis.” Critical care explorations (2026). PMID: 42390290 ↗

    L4CASE_REPORTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
  217. [217]

    Huang P, He SS, Feng S et al.. “Efficacy and Safety of Shenfu Injection in Patients with Septic Shock: A Randomized Controlled Open-Label Trial with Network Pharmacology-Based Mechanistic Insights.” Chinese journal of integrative medicine (2026). PMID: 41870792 ↗

    L1RCTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
  218. [218]

    Li BH, Liang ZY, Chen LL et al.. “[Application and comparative study of critical care ultrasound and noninvasive cardiac output monitoring in fluid resuscitation of neonatal septic shock: a randomized controlled trial].” Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics (2026). PMID: 41766144 ↗

    L1RCTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
  219. [219]

    Antcliffe DB, Santhakumaran S, Orme RML et al.. “Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial.” Intensive care medicine (2019). PMID: 31428804 ↗

    L3RCTCited in: Severity Scoring & Risk Stratification (ICU Scores), Definitive Therapy & Source Control of the Inciting Insult
  220. [220]

    Pappalardo F, Crivellari M, Di Prima AL et al.. “Protein C zymogen in severe sepsis: a double-blinded, placebo-controlled, randomized study.” Intensive care medicine (2016). PMID: 27344436 ↗

    L1RCTCited in: Severity Scoring & Risk Stratification (ICU Scores), Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  221. [221]

    Moreno R, Sprung CL, Annane D et al.. “Time course of organ failure in patients with septic shock treated with hydrocortisone: results of the Corticus study.” Intensive care medicine (2011). PMID: 21847649 ↗

    L1RCTCited in: Severity Scoring & Risk Stratification (ICU Scores)
  222. [222]

    Masson S, Caironi P, Fanizza C et al.. “Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial.” Intensive care medicine (2014). PMID: 25319385 ↗

    L3RCTCited in: Severity Scoring & Risk Stratification (ICU Scores)
  223. [223]

    Kethireddy S, Bilgili B, Sees A et al.. “Culture-Negative Septic Shock Compared With Culture-Positive Septic Shock: A Retrospective Cohort Study.” Critical care medicine (2018). PMID: 29293143 ↗

    L3COHORTCited in: Severity Scoring & Risk Stratification (ICU Scores), Definitive Therapy & Source Control of the Inciting Insult
  224. [224]

    Barbier F, Buetti N, Dupuis C et al.. “Prognostic Impact of Early Appropriate Antimicrobial Therapy in Critically Ill Patients With Nosocomial Pneumonia Due to Gram-Negative Pathogens: A Multicenter Cohort Study.” Critical care medicine (2025). PMID: 40009040 ↗

    L3COHORTCited in: Severity Scoring & Risk Stratification (ICU Scores), Definitive Therapy & Source Control of the Inciting Insult, Complications & Iatrogenesis
  225. [225]

    Kuipers S, Klein Klouwenberg PM, Cremer OL. “Incidence, risk factors and outcomes of new-onset atrial fibrillation in patients with sepsis: a systematic review.” Critical care (London, England) (2014). PMID: 25498795 ↗

    L3SR_OBSCited in: Severity Scoring & Risk Stratification (ICU Scores)
  226. [226]

    Morgan RW, Reeder RW, Carcillo JA et al.. “Outcomes, Characteristics, and Physiology of In-Hospital Cardiac Arrest in Children With Sepsis.” Critical care medicine (2025). PMID: 40558671 ↗

    L2OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores)
  227. [227]

    Di Pasquale M, Ferrer M, Esperatti M et al.. “Assessment of severity of ICU-acquired pneumonia and association with etiology.” Critical care medicine (2014). PMID: 23989176 ↗

    L2OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores), Complications & Iatrogenesis
  228. [228]

    Wong HR, Lindsell CJ, Pettilä V et al.. “A multibiomarker-based outcome risk stratification model for adult septic shock*.” Critical care medicine (2014). PMID: 24335447 ↗

    L3OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores)
  229. [229]

    van Zanten AR, Brinkman S, Arbous MS et al.. “Guideline bundles adherence and mortality in severe sepsis and septic shock.” Critical care medicine (2014). PMID: 24670937 ↗

    L2OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores)
  230. [230]

    Zuber B, Tran TC, Aegerter P et al.. “Impact of case volume on survival of septic shock in patients with malignancies.” Critical care medicine (2012). PMID: 21926606 ↗

    L3OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores)
  231. [231]

    Damas P, Ledoux D, Nys M et al.. “Intensive care unit acquired infection and organ failure.” Intensive care medicine (2008). PMID: 18259728 ↗

    L3OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores), Complications & Iatrogenesis
  232. [232]

    Vignon P, Charron C, Legras A et al.. “Left ventricular diastolic dysfunction is prevalent but not associated with mortality in patients with septic shock.” Intensive care medicine (2025). PMID: 39774865 ↗

    L2OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores), Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  233. [233]

    Vassiliou AG, Maniatis NA, Kotanidou A et al.. “Endothelial protein C receptor polymorphisms and risk of severe sepsis in critically ill patients.” Intensive care medicine (2013). PMID: 23881209 ↗

    L3OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores)
  234. [234]

    Azoulay E, Lemiale V, Mokart D et al.. “Acute respiratory distress syndrome in patients with malignancies.” Intensive care medicine (2014). PMID: 24898895 ↗

    L3OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores)
  235. [235]

    Que YA, Guessous I, Dupuis-Lozeron E et al.. “Prognostication of Mortality in Critically Ill Patients With Severe Infections.” Chest (2015). PMID: 26065577 ↗

    L2OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores)
  236. [236]

    Fernando SM, Reardon PM, Rochwerg B et al.. “Sepsis-3 Septic Shock Criteria and Associated Mortality Among Infected Hospitalized Patients Assessed by a Rapid Response Team.” Chest (2018). PMID: 29778659 ↗

    L3OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores), Special Populations
  237. [237]

    Kenneally C, Rosini JM, Skrupky LP et al.. “Analysis of 30-day mortality for clostridium difficile-associated disease in the ICU setting.” Chest (2007). PMID: 17573523 ↗

    L3OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores)
  238. [238]

    Farzanegan B, Shafigh N, Hasheminik M et al.. “The combined effect of statin and vitamin C in patients with pulmonary septic shock: a single-center, double-blind clinical trial.” BMC infectious diseases (2025). PMID: 41136950 ↗

    L1RCTCited in: Severity Scoring & Risk Stratification (ICU Scores), Definitive Therapy & Source Control of the Inciting Insult
  239. [239]

    Saraiva LT, da Silva Costa WN, Grams ST et al.. “Discriminatory Characteristics of Responders and Nonresponders of Patients With Sepsis to Neuromuscular Electrical Stimulation: A Subanalysis of a Randomized Controlled Double-Blinded Trial.” Archives of physical medicine and rehabilitation (2025). PMID: 41083041 ↗

    L2RCTCited in: Severity Scoring & Risk Stratification (ICU Scores), Definitive Therapy & Source Control of the Inciting Insult
  240. [240]

    Safabakhsh M, Shab-Bidar S, Rohani P et al.. “Effect of probiotics on intestinal permeability in critically ill children with sepsis: preliminary results from a double-blind, placebo-controlled trial.” European journal of nutrition (2025). PMID: 40986080 ↗

    L1RCTCited in: Severity Scoring & Risk Stratification (ICU Scores), Definitive Therapy & Source Control of the Inciting Insult, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  241. [241]

    Du C, Li X. “Comparative prognostic evaluation of SOFA and PSS scores in pediatric septic shock: A retrospective study.” Advances in clinical and experimental medicine : official organ Wroclaw Medical University (2026). PMID: 41524716 ↗

    L3COHORTCited in: Severity Scoring & Risk Stratification (ICU Scores)
  242. [242]

    Duan J, Chen L, Liu X et al.. “An updated HACOR score for predicting the failure of noninvasive ventilation: a multicenter prospective observational study.” Critical care (London, England) (2022). PMID: 35786223 ↗

    L2OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores)
  243. [243]

    Zimmermann T, Kaufmann P, Amacher SA et al.. “Sex differences in the SOFA score of ICU patients with sepsis or septic shock: a nationwide analysis.” Critical care (London, England) (2024). PMID: 38937819 ↗

    L3OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores)
  244. [244]

    Le Goff M, Martino F, Rossi G et al.. “Prognosis of liver abscess in the intensive care unit (POLAIR), a multicentre observational study.” Critical care (London, England) (2025). PMID: 40197508 ↗

    L3OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores), Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  245. [245]

    Mekontso Dessap A, AlShamsi F, Belletti A et al.. “European Society of Intensive Care Medicine (ESICM) 2025 clinical practice guideline on fluid therapy in adult critically ill patients: part 2-the volume of resuscitation fluids.” Intensive care medicine (2025). PMID: 40163133 ↗

    L1GUIDELINECited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
  246. [246]

    Sankar J, Muralidharan J, Lalitha AV et al.. “Multiple Electrolytes Solution Versus Saline as Bolus Fluid for Resuscitation in Pediatric Septic Shock: A Multicenter Randomized Clinical Trial.” Critical care medicine (2023). PMID: 37294145 ↗

    L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
  247. [247]

    Hajjar LA, Zambolim C, Belletti A et al.. “Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients: The VANCS II Randomized Clinical Trial.” Critical care medicine (2019). PMID: 31609774 ↗

    L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
  248. [248]

    Rehberg S, Frank S, Černý V et al.. “Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP).” Intensive care medicine (2024). PMID: 39297945 ↗

    L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
  249. [249]

    Antcliffe DB, Burnham KL, Al-Beidh F et al.. “Transcriptomic Signatures in Sepsis and a Differential Response to Steroids. From the VANISH Randomized Trial.” American journal of respiratory and critical care medicine (2019). PMID: 30365341 ↗

    L3RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
  250. [250]

    Moskowitz A, Berg KM, Grossestreuer AV et al.. “Thiamine for Renal Protection in Septic Shock (TRPSS): A Randomized, Placebo-controlled, Clinical Trial.” American journal of respiratory and critical care medicine (2023). PMID: 37364280 ↗

    L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
  251. [251]

    Schortgen F, Clabault K, Katsahian S et al.. “Fever control using external cooling in septic shock: a randomized controlled trial.” American journal of respiratory and critical care medicine (2012). PMID: 22366046 ↗

    L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  252. [252]

    Kellum JA, Chawla LS, Keener C et al.. “The Effects of Alternative Resuscitation Strategies on Acute Kidney Injury in Patients with Septic Shock.” American journal of respiratory and critical care medicine (2016). PMID: 26398704 ↗

    L2RCTCited in: Acute Resuscitation & Time-Critical Management, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  253. [253]

    Douglas IS, Alapat PM, Corl KA et al.. “Fluid Response Evaluation in Sepsis Hypotension and Shock: A Randomized Clinical Trial.” Chest (2020). PMID: 32353418 ↗

    L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  254. [254]

    Ezz Al-Regal AR, Ramzy EA, Atia AAA et al.. “Dexmedetomidine for Reducing Mortality in Patients With Septic Shock: A Randomized Controlled Trial (DecatSepsis).” Chest (2024). PMID: 39004217 ↗

    L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  255. [255]

    Sehgal IS, Basumatary NM, Dhooria S et al.. “A Randomized Trial of Mycobacterium w in Severe Presumed Gram-Negative Sepsis.” Chest (2021). PMID: 33852919 ↗

    L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
  256. [256]

    Annane D, Renault A, Brun-Buisson C et al.. “Hydrocortisone plus Fludrocortisone for Adults with Septic Shock.” The New England journal of medicine (2018). PMID: 29490185 ↗

    L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  257. [257]

    De Backer D, Biston P, Devriendt J et al.. “Comparison of dopamine and norepinephrine in the treatment of shock.” The New England journal of medicine (2010). PMID: 20200382 ↗

    L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
  258. [258]

    Russell JA, Walley KR, Singer J et al.. “Vasopressin versus norepinephrine infusion in patients with septic shock.” The New England journal of medicine (2008). PMID: 18305265 ↗

    L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
  259. [259]

    Meyhoff TS, Hjortrup PB, Wetterslev J et al.. “Restriction of Intravenous Fluid in ICU Patients with Septic Shock.” The New England journal of medicine (2022). PMID: 35709019 ↗

    L1RCTCited in: Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Complications & Iatrogenesis
  260. [260]

    Sprung CL, Annane D, Keh D et al.. “Hydrocortisone therapy for patients with septic shock.” The New England journal of medicine (2008). PMID: 18184957 ↗

    L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
  261. [261]

    Asfar P, Meziani F, Hamel JF et al.. “High versus low blood-pressure target in patients with septic shock.” The New England journal of medicine (2014). PMID: 24635770 ↗

    L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  262. [262]

    Ranieri VM, Thompson BT, Barie PS et al.. “Drotrecogin alfa (activated) in adults with septic shock.” The New England journal of medicine (2012). PMID: 22616830 ↗

    L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
  263. [263]

    Gendreau S, Frapard T, Carteaux G et al.. “Geo-economic Influence on the Effect of Fluid Volume for Sepsis Resuscitation: A Meta-Analysis.” American journal of respiratory and critical care medicine (2024). PMID: 38259196 ↗

    L1SR_OBSCited in: Acute Resuscitation & Time-Critical Management
  264. [264]

    Annane D, Vignon P, Renault A et al.. “Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial.” Lancet (London, England) (2007). PMID: 17720019 ↗

    L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
  265. [265]

    Cruz DN, Antonelli M, Fumagalli R et al.. “Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial.” JAMA (2009). PMID: 19531784 ↗

    L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  266. [266]

    Ahn C, Yu G, Shin TG et al.. “Comparison of Early and Late Norepinephrine Administration in Patients With Septic Shock: A Systematic Review and Meta-Analysis.” Chest (2024). PMID: 38972348 ↗

    L1SR_OBSCited in: Acute Resuscitation & Time-Critical Management
  267. [267]

    Kotani Y, Belletti A, D'Amico F et al.. “Non-adrenergic vasopressors for vasodilatory shock or perioperative vasoplegia: a meta-analysis of randomized controlled trials.” Critical care (London, England) (2024). PMID: 39736782 ↗

    L1SR_MA_RCTCited in: Acute Resuscitation & Time-Critical Management
  268. [268]

    Ibarra-Estrada M, Kattan E, Aguilera-González P et al.. “Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial.” Critical care (London, England) (2023). PMID: 36915146 ↗

    L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
  269. [269]

    Jorda A, Douglas IS, Staudinger T et al.. “Fluid management for sepsis-induced hypotension in patients with advanced chronic kidney disease: a secondary analysis of the CLOVERS trial.” Critical care (London, England) (2024). PMID: 38992663 ↗

    L2RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
  270. [270]

    Davis AL, Carcillo JA, Aneja RK et al.. “American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock.” Critical care medicine (2017). PMID: 28509730 ↗

    L1OTHERCited in: Acute Resuscitation & Time-Critical Management
  271. [271]

    Sanchez E C, Taha A, Tolba Y et al.. “Assessment of Tissue Perfusion Pressure in Patients With Septic Shock: Beyond Mean Arterial Pressure.” Critical care medicine (2025). PMID: 40668153 ↗

    L5REVIEW_NARRATIVECited in: Acute Resuscitation & Time-Critical Management
  272. [272]

    Ferrer R, Martin-Loeches I, Phillips G et al.. “Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program.” Critical care medicine (2014). PMID: 24717459 ↗

    L2OTHERCited in: Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult
  273. [273]

    Kuttab HI, Lykins JD, Hughes MD et al.. “Evaluation and Predictors of Fluid Resuscitation in Patients With Severe Sepsis and Septic Shock.” Critical care medicine (2019). PMID: 31393324 ↗

    L3OTHERCited in: Acute Resuscitation & Time-Critical Management
  274. [274]

    Im Y, Kang D, Ko RE et al.. “Time-to-antibiotics and clinical outcomes in patients with sepsis and septic shock: a prospective nationwide multicenter cohort study.” Critical care (London, England) (2022). PMID: 35027073 ↗

    L2COHORTCited in: Acute Resuscitation & Time-Critical Management
  275. [275]

    Munroe ES, Hyzy RC, Semler MW et al.. “Evolving Management Practices for Early Sepsis-induced Hypoperfusion: A Narrative Review.” American journal of respiratory and critical care medicine (2023). PMID: 36812500 ↗

    L5REVIEW_NARRATIVECited in: Acute Resuscitation & Time-Critical Management
  276. [276]

    Byrne L, Obonyo NG, Diab SD et al.. “Unintended Consequences: Fluid Resuscitation Worsens Shock in an Ovine Model of Endotoxemia.” American journal of respiratory and critical care medicine (2018). PMID: 29882682 ↗

    L5OTHERCited in: Acute Resuscitation & Time-Critical Management
  277. [277]

    Teja B, Bosch NA, Walkey AJ. “How We Escalate Vasopressor and Corticosteroid Therapy in Patients With Septic Shock.” Chest (2022). PMID: 36162481 ↗

    L5REVIEW_NARRATIVECited in: Acute Resuscitation & Time-Critical Management
  278. [278]

    Yealy DM, Kellum JA, Huang DT et al.. “A randomized trial of protocol-based care for early septic shock.” The New England journal of medicine (2014). PMID: 24635773 ↗

    L1OTHERCited in: Acute Resuscitation & Time-Critical Management
  279. [279]

    Boussina A, Allison C, Quintero K et al.. “Medical Record Abstraction for Quality Improvement in Sepsis Care Using Artificial Intelligence: A Cluster Randomized Trial.” JAMA network open (2026). PMID: 42348212 ↗

    L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
  280. [280]

    Christensen J, Sivapalan P, Meyhoff TS et al.. “Restrictive versus standard intravenous fluid therapy and NTproBNP in ICU patients with septic shock - a sub-study of the randomised CLASSIC trial.” BMC anesthesiology (2026). PMID: 41987014 ↗

    L1RCTCited in: Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Special Populations
  281. [281]

    Neyra JA, Legrand M, Tidswell MA et al.. “Polymyxin B haemoadsorption in endotoxic septic shock (Tigris): a multicentre, open-label, Bayesian, randomised, controlled, phase 3 trial.” The Lancet. Respiratory medicine (2026). PMID: 41887242 ↗

    L1RCTCited in: Acute Resuscitation & Time-Critical Management
  282. [282]

    Lotz C, Heckelmann J, Lendzian C et al.. “Clinical and Immunologic Effects of Extracorporeal Cytokine Removal in Patients with Septic Shock: A Randomized Controlled Trial.” Shock (Augusta, Ga.) (2026). PMID: 41670614 ↗

    L1RCTCited in: Acute Resuscitation & Time-Critical Management
  283. [283]

    Whitehouse T, Hossain A, Perkins GD et al.. “Landiolol and Organ Failure in Patients With Septic Shock: The STRESS-L Randomized Clinical Trial.” JAMA (2023). PMID: 37877587 ↗

    L1OTHERCited in: Acute Resuscitation & Time-Critical Management
  284. [284]

    Luo JC, Mou T, Li M et al.. “Recombinant human brain natriuretic peptide for the recovery stage of septic shock: an interventional study protocol.” BMJ open (2026). PMID: 42192636 ↗

    L5TRIAL_NONRANDOMCited in: Acute Resuscitation & Time-Critical Management
  285. [285]

    Tekin A, Halpern G, Gowda D et al.. “Midodrine for Sepsis Treatment and Early Vasopressor Weaning (MID-STEP): protocol for a pragmatic randomised clinical trial.” BMJ open (2026). PMID: 42020133 ↗

    L5TRIAL_NONRANDOMCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
  286. [286]

    Menon K, Agus MSD, O'Hearn K et al.. “Stress Hydrocortisone in Pediatric Septic Shock: Protocol for a Pragmatic, Multicenter, International, Randomized, Double-Blinded, Placebo-Controlled Interventional Trial.” Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies (2025). PMID: 41504575 ↗

    L5TRIAL_NONRANDOMCited in: Acute Resuscitation & Time-Critical Management
  287. [287]

    Desfosses M, Røislien J. “An overview of reviews of Angiotensin II in distributive shock.” BMC anesthesiology (2026). PMID: 41942842 ↗

    L2SR_OBSCited in: Acute Resuscitation & Time-Critical Management
  288. [288]

    Süffert LC, Pergher EAB, de Abreu HS et al.. “Low-dose corticosteroids in cirrhotic patients with septic shock or vasopressor-dependent shock: A systematic review and meta-analysis.” Journal of critical care (2025). PMID: 41412001 ↗

    L2SR_OBSCited in: Acute Resuscitation & Time-Critical Management
  289. [289]

    Li D, Li X, Cui W et al.. “Liberal versus conservative fluid therapy in adults and children with sepsis or septic shock.” The Cochrane database of systematic reviews (2018). PMID: 30536956 ↗

    L1SR_OBSCited in: Acute Resuscitation & Time-Critical Management
  290. [290]

    Monnet X, Lai C, Teboul JL. “How I personalize fluid therapy in septic shock?” Critical care (London, England) (2023). PMID: 36964573 ↗

    L5REVIEW_NARRATIVECited in: Acute Resuscitation & Time-Critical Management
  291. [291]

    Arias-Ortiz J, Vincent JL. “Administration of methylene blue in septic shock: pros and cons.” Critical care (London, England) (2024). PMID: 38365828 ↗

    L5REVIEW_NARRATIVECited in: Acute Resuscitation & Time-Critical Management
  292. [292]

    Garnacho-Montero J, Dimopoulos G, Poulakou G et al.. “Task force on management and prevention of Acinetobacter baumannii infections in the ICU.” Intensive care medicine (2015). PMID: 26438224 ↗

    L5GUIDELINECited in: Definitive Therapy & Source Control of the Inciting Insult
  293. [293]

    Iapichino G, Albicini M, Umbrello M et al.. “Tight glycemic control does not affect asymmetric-dimethylarginine in septic patients.” Intensive care medicine (2008). PMID: 18504551 ↗

    L1SR_MA_RCTCited in: Definitive Therapy & Source Control of the Inciting Insult, Special Populations
  294. [294]

    Sivapalan P, Kaas-Hansen BS, Meyhoff TS et al.. “Effects of IV Fluid Restriction According to Standard Fluid Treatment Intensity Across Conservative Versus Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care (CLASSIC) Trial Sites.” Critical care medicine (2025). PMID: 40272936 ↗

    L2RCTCited in: Definitive Therapy & Source Control of the Inciting Insult, Complications & Iatrogenesis, Special Populations
  295. [295]

    Ahlstedt C, Sivapalan P, Kriz M et al.. “Effects of restrictive fluid therapy on the time to resolution of hyperlactatemia in ICU patients with septic shock. A secondary post hoc analysis of the CLASSIC randomized trial.” Intensive care medicine (2024). PMID: 38598125 ↗

    L2RCTCited in: Definitive Therapy & Source Control of the Inciting Insult
  296. [296]

    Yildizdas D, Yapicioglu H, Celik U et al.. “Terlipressin as a rescue therapy for catecholamine-resistant septic shock in children.” Intensive care medicine (2007). PMID: 18092150 ↗

    L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  297. [297]

    Garbero E, Livigni S, Ferrari F et al.. “High dose coupled plasma filtration and adsorption in septic shock patients. Results of the COMPACT-2: a multicentre, adaptive, randomised clinical trial.” Intensive care medicine (2021). PMID: 34601619 ↗

    L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  298. [298]

    Kumar A, Safdar N, Kethireddy S et al.. “A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study.” Critical care medicine (2010). PMID: 20562695 ↗

    L2SR_OBSCited in: Definitive Therapy & Source Control of the Inciting Insult
  299. [299]

    Tongyoo S, Chayakul C, Aritajati T et al.. “Adjunctive terlipressin versus placebo in the treatment of refractory septic shock: a randomized, placebo-controlled trial.” Critical care (London, England) (2025). PMID: 41121365 ↗

    L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
  300. [300]

    Rüddel H, Thomas-Rüddel DO, Reinhart K et al.. “Adverse effects of delayed antimicrobial treatment and surgical source control in adults with sepsis: results of a planned secondary analysis of a cluster-randomized controlled trial.” Critical care (London, England) (2022). PMID: 35227308 ↗

    L2RCTCited in: Definitive Therapy & Source Control of the Inciting Insult
  301. [301]

    Yu Y, Zhu C, Hong Y et al.. “Effectiveness of anisodamine for the treatment of critically ill patients with septic shock: a multicentre randomized controlled trial.” Critical care (London, England) (2021). PMID: 34579741 ↗

    L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  302. [302]

    Prkno A, Wacker C, Brunkhorst FM et al.. “Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock--a systematic review and meta-analysis.” Critical care (London, England) (2013). PMID: 24330744 ↗

    L1SR_OBSCited in: Definitive Therapy & Source Control of the Inciting Insult
  303. [303]

    Song MJ, Seo WI, Jang Y et al.. “RBC Transfusion Practices in Critically Ill Patients With Sepsis.” Critical care medicine (2025). PMID: 41090988 ↗

    L2OTHERCited in: Definitive Therapy & Source Control of the Inciting Insult
  304. [304]

    Timsit JF, Ruppé E, Barbier F et al.. “Bloodstream infections in critically ill patients: an expert statement.” Intensive care medicine (2020). PMID: 32047941 ↗

    L5OTHERCited in: Definitive Therapy & Source Control of the Inciting Insult
  305. [305]

    Barbier F, Dupuis C, Buetti N et al.. “Single-drug versus combination antimicrobial therapy in critically ill patients with hospital-acquired pneumonia and ventilator-associated pneumonia due to Gram-negative pathogens: a multicenter retrospective cohort study.” Critical care (London, England) (2024). PMID: 38172969 ↗

    L3COHORTCited in: Definitive Therapy & Source Control of the Inciting Insult, Complications & Iatrogenesis
  306. [306]

    Calabretta D, Cilloniz C, Gabarrus A et al.. “Impact of Empirical Treatment Recommendations From 2017 European Guidelines for Nosocomial Pneumonia.” Chest (2024). PMID: 39461555 ↗

    L3OTHERCited in: Definitive Therapy & Source Control of the Inciting Insult, Complications & Iatrogenesis
  307. [307]

    Müller MM, Pinto R, Lamontagne F et al.. “Vitamin C Does Not Affect Platelet Counts in Patients With Sepsis: A Post hoc Analysis of the Lessening Organ Dysfunction With Vitamin C Randomized Trial.” Critical care explorations (2025). PMID: 40927646 ↗

    L2RCTCited in: Definitive Therapy & Source Control of the Inciting Insult
  308. [308]

    Sankar J, Manoharan A, Lodha R et al.. “Vitamin C Versus Placebo in Pediatric Septic Shock (VITACiPS) - A Randomised Controlled Trial.” Journal of intensive care medicine (2025). PMID: 40708328 ↗

    L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult
  309. [309]

    Kollef MH, Shorr AF, Bassetti M et al.. “Timing of antibiotic therapy in the ICU.” Critical care (London, England) (2021). PMID: 34654462 ↗

    L5REVIEW_NARRATIVECited in: Definitive Therapy & Source Control of the Inciting Insult
  310. [310]

    Dellinger RP, Carlet JM, Masur H et al.. “Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.” Critical care medicine (2004). PMID: 15090974 ↗

    L5GUIDELINECited in: History and Evolution of Treatment
  311. [311]

    Díaz-Gómez JL, Sharif S, Ablordeppey E et al.. “Society of Critical Care Medicine Guidelines on Adult Critical Care Ultrasonography: Focused Update 2024.” Critical care medicine (2025). PMID: 39982182 ↗

    L1GUIDELINECited in: History and Evolution of Treatment
  312. [312]

    Barochia AV, Cui X, Vitberg D et al.. “Bundled care for septic shock: an analysis of clinical trials.” Critical care medicine (2010). PMID: 20029343 ↗

    L2TRIAL_NONRANDOMCited in: History and Evolution of Treatment
  313. [313]

    Kirov MY, Evgenov OV, Evgenov NV et al.. “Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study.” Critical care medicine (2001). PMID: 11588440 ↗

    L1RCTCited in: History and Evolution of Treatment
  314. [314]

    Hagel S, Bach F, Brenner T et al.. “Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial.” Intensive care medicine (2022). PMID: 35106617 ↗

    L1RCTCited in: History and Evolution of Treatment
  315. [315]

    Liu ZM, Chen J, Kou Q et al.. “Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial.” Intensive care medicine (2018). PMID: 29971593 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications & Iatrogenesis
  316. [316]

    Leaf DE, Raed A, Donnino MW et al.. “Randomized controlled trial of calcitriol in severe sepsis.” American journal of respiratory and critical care medicine (2014). PMID: 25029202 ↗

    L1RCTCited in: History and Evolution of Treatment
  317. [317]

    Ferrer M, Esquinas A, Arancibia F et al.. “Noninvasive ventilation during persistent weaning failure: a randomized controlled trial.” American journal of respiratory and critical care medicine (2003). PMID: 12689847 ↗

    L1RCTCited in: History and Evolution of Treatment
  318. [318]

    Ortolani O, Conti A, De Gaudio AR et al.. “The effect of glutathione and N-acetylcysteine on lipoperoxidative damage in patients with early septic shock.” American journal of respiratory and critical care medicine (2000). PMID: 10852765 ↗

    L1RCTCited in: History and Evolution of Treatment
  319. [319]

    Cohen J, Bellomo R, Billot L et al.. “Plasma Cortisol, Aldosterone, and Ascorbic Acid Concentrations in Patients with Septic Shock Do Not Predict Treatment Effect of Hydrocortisone on Mortality. A Nested Cohort Study.” American journal of respiratory and critical care medicine (2020). PMID: 32396775 ↗

    L2RCTCited in: History and Evolution of Treatment
  320. [320]

    Annane D, Timsit JF, Megarbane B et al.. “Recombinant human activated protein C for adults with septic shock: a randomized controlled trial.” American journal of respiratory and critical care medicine (2013). PMID: 23525934 ↗

    L1RCTCited in: History and Evolution of Treatment
  321. [321]

    Meisel C, Schefold JC, Pschowski R et al.. “Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial.” American journal of respiratory and critical care medicine (2009). PMID: 19590022 ↗

    L1RCTCited in: History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  322. [322]

    Simou E, Leonardi-Bee J, Britton J. “The Effect of Alcohol Consumption on the Risk of ARDS: A Systematic Review and Meta-Analysis.” Chest (2017). PMID: 29288645 ↗

    L2SR_OBSCited in: History and Evolution of Treatment
  323. [323]

    Martin C, Papazian L, Perrin G et al.. “Norepinephrine or dopamine for the treatment of hyperdynamic septic shock?” Chest (1993). PMID: 8404107 ↗

    L1RCTCited in: History and Evolution of Treatment
  324. [324]

    Wunderink R, Leeper K, Schein R et al.. “Filgrastim in patients with pneumonia and severe sepsis or septic shock.” Chest (2001). PMID: 11171733 ↗

    L1RCTCited in: History and Evolution of Treatment
  325. [325]

    Fourrier F, Chopin C, Huart JJ et al.. “Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation.” Chest (1993). PMID: 8365305 ↗

    L1RCTCited in: History and Evolution of Treatment
  326. [326]

    Tuchschmidt J, Fried J, Astiz M et al.. “Elevation of cardiac output and oxygen delivery improves outcome in septic shock.” Chest (1992). PMID: 1623756 ↗

    L1RCTCited in: History and Evolution of Treatment
  327. [327]

    Puskarich MA, Trzeciak S, Shapiro NI et al.. “Whole blood lactate kinetics in patients undergoing quantitative resuscitation for severe sepsis and septic shock.” Chest (2013). PMID: 23740148 ↗

    L2RCTCited in: History and Evolution of Treatment
  328. [328]

    Attard G, Murphy L, Clarke NW et al.. “Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.” Lancet (London, England) (2021). PMID: 34953525 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  329. [329]

    Rivers E, Nguyen B, Havstad S et al.. “Early goal-directed therapy in the treatment of severe sepsis and septic shock.” The New England journal of medicine (2001). PMID: 11794169 ↗

    L1RCTCited in: History and Evolution of Treatment
  330. [330]

    Venkatesh B, Finfer S, Cohen J et al.. “Adjunctive Glucocorticoid Therapy in Patients with Septic Shock.” The New England journal of medicine (2018). PMID: 29347874 ↗

    L1RCTCited in: History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  331. [331]

    Caironi P, Tognoni G, Masson S et al.. “Albumin replacement in patients with severe sepsis or septic shock.” The New England journal of medicine (2014). PMID: 24635772 ↗

    L1RCTCited in: History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  332. [332]

    Rugo HS, Bardia A, Marmé F et al.. “Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.” Lancet (London, England) (2023). PMID: 37633306 ↗

    L1RCTCited in: History and Evolution of Treatment
  333. [333]

    Thompson GR, Soriano A, Cornely OA et al.. “Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.” Lancet (London, England) (2022). PMID: 36442484 ↗

    L1RCTCited in: History and Evolution of Treatment
  334. [334]

    Baudin E, Goichot B, Berruti A et al.. “Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.” Lancet (London, England) (2024). PMID: 38402886 ↗

    L1RCTCited in: History and Evolution of Treatment
  335. [335]

    DeMaria A, Carven DE, Heffernan JJ et al.. “Naloxone versus placebo in treatment of septic shock.” Lancet (London, England) (1985). PMID: 2861315 ↗

    L1RCTCited in: History and Evolution of Treatment
  336. [336]

    Roberts DE, Dobson KE, Hall KW et al.. “Effects of prolonged naloxone infusion in septic shock.” Lancet (London, England) (1988). PMID: 2901565 ↗

    L1RCTCited in: History and Evolution of Treatment
  337. [337]

    Abraham E, Anzueto A, Gutierrez G et al.. “Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.” Lancet (London, England) (1998). PMID: 9734938 ↗

    L1RCTCited in: History and Evolution of Treatment
  338. [338]

    Baumgartner JD, Glauser MP, McCutchan JA et al.. “Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid.” Lancet (London, England) (1985). PMID: 2861523 ↗

    L1RCTCited in: History and Evolution of Treatment
  339. [339]

    Schortgen F, Lacherade JC, Bruneel F et al.. “Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study.” Lancet (London, England) (2001). PMID: 11289347 ↗

    L1RCTCited in: History and Evolution of Treatment
  340. [340]

    Lachman E, Pitsoe SB, Gaffin SL. “Anti-lipopolysaccharide immunotherapy in management of septic shock of obstetric and gynaecological origin.” Lancet (London, England) (1984). PMID: 6143965 ↗

    L2RCTCited in: History and Evolution of Treatment
  341. [341]

    Day NP, Phu NH, Bethell DP et al.. “The effects of dopamine and adrenaline infusions on acid-base balance and systemic haemodynamics in severe infection.” Lancet (London, England) (1996). PMID: 8684198 ↗

    L1RCTCited in: History and Evolution of Treatment
  342. [342]

    Annane D, Sébille V, Charpentier C et al.. “Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.” JAMA (2002). PMID: 12186604 ↗

    L1RCTCited in: History and Evolution of Treatment
  343. [343]

    Dellinger RP, Bagshaw SM, Antonelli M et al.. “Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial.” JAMA (2018). PMID: 30304428 ↗

    L1RCTCited in: History and Evolution of Treatment
  344. [344]

    Quezado ZM, Natanson C, Alling DW et al.. “A controlled trial of HA-1A in a canine model of gram-negative septic shock.” JAMA (1993). PMID: 8474201 ↗

    L5RCTCited in: History and Evolution of Treatment
  345. [345]

    Annane D, Cariou A, Maxime V et al.. “Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial.” JAMA (2010). PMID: 20103758 ↗

    L1RCTCited in: History and Evolution of Treatment
  346. [346]

    Moskowitz A, Huang DT, Hou PC et al.. “Effect of Ascorbic Acid, Corticosteroids, and Thiamine on Organ Injury in Septic Shock: The ACTS Randomized Clinical Trial.” JAMA (2020). PMID: 32809003 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications & Iatrogenesis
  347. [347]

    Roux D, Benichou N, Hajage D et al.. “Impact of renal replacement therapy strategy on beta-lactam plasma concentrations: the BETAKIKI study-an ancillary study of a randomized controlled trial.” Annals of intensive care (2023). PMID: 36840825 ↗

    L2RCTCited in: History and Evolution of Treatment
  348. [348]

    Vallabhajosyula S, Kumar M, Pandompatam G et al.. “Prognostic impact of isolated right ventricular dysfunction in sepsis and septic shock: an 8-year historical cohort study.” Annals of intensive care (2017). PMID: 28884343 ↗

    L2COHORTCited in: History and Evolution of Treatment
  349. [349]

    Llitjos JF, Bredin S, Lascarrou JB et al.. “Increased susceptibility to intensive care unit-acquired pneumonia in severe COVID-19 patients: a multicentre retrospective cohort study.” Annals of intensive care (2021). PMID: 33512602 ↗

    L2COHORTCited in: History and Evolution of Treatment
  350. [350]

    Viswanathan M, Kahwati L, Jahn B et al.. “Universal screening for SARS-CoV-2 infection: a rapid review.” The Cochrane database of systematic reviews (2020). PMID: 33502003 ↗

    L2SR_OBSCited in: History and Evolution of Treatment
  351. [351]

    Moutinho A, Martins F, Fontes J et al.. “[Management of the Patient with Suspected Sepsis or Septic Shock: Clinical Recommendations for the Portuguese Prehospital Setting].” Acta medica portuguesa (2026). PMID: 42044523 ↗

    L1GUIDELINECited in: History and Evolution of Treatment
  352. [352]

    Byrne L, Van Haren F. “Fluid resuscitation in human sepsis: Time to rewrite history?” Annals of intensive care (2017). PMID: 28050897 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  353. [353]

    Crosignani A, Spina S, Marrazzo F et al.. “Intravenous fluid therapy in patients with severe acute pancreatitis admitted to the intensive care unit: a narrative review.” Annals of intensive care (2022). PMID: 36251136 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  354. [354]

    Ronco C, Bellomo R. “Hemoperfusion: technical aspects and state of the art.” Critical care (London, England) (2022). PMID: 35549999 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  355. [355]

    Bottari G, Ranieri VM, Ince C et al.. “Use of extracorporeal blood purification therapies in sepsis: the current paradigm, available evidence, and future perspectives.” Critical care (London, England) (2024). PMID: 39722012 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  356. [356]

    Wongtirawit N, Inyu W, Prajantasen U et al.. “HA-330 hemoadsorption in septic shock requiring high-dose norepinephrine: a multicenter randomized controlled trial (CLEANSE).” Critical care (London, England) (2026). PMID: 42277846 ↗

    L1RCTCited in: History and Evolution of Treatment
  357. [357]

    Thanasai J, Chanthot C, Chittamma A et al.. “Serum Procalcitonin in Culture-Confirmed Melioidosis: A Systematic Review and Meta-Analysis with Narrative Evaluation of Clinical and Prognostic Implications.” Diseases (Basel, Switzerland) (2026). PMID: 42041611 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  358. [358]

    Mowafy HL, Garin N, Katsounas A et al.. “Sex-related disparities in sepsis in western Europe: A systematic review and meta-analysis.” European journal of internal medicine (2026). PMID: 42115064 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  359. [359]

    Anton GI, Radu R, Ceban E et al.. “Efficacy and Safety of Meropenem in Pregnant Women with Upper Urinary Tract Infections: A Retrospective Cohort Study in Romania.” Antibiotics (Basel, Switzerland) (2026). PMID: 42353734 ↗

    L2COHORTCited in: History and Evolution of Treatment
  360. [360]

    Zhou L, Li S, Ding Q et al.. “A comparison of pediatric sepsis definitions based on systemic inflammatory response syndrome and Phoenix criteria: a single-center PICU retrospective study.” Italian journal of pediatrics (2026). PMID: 42321878 ↗

    L2COHORTCited in: History and Evolution of Treatment
  361. [361]

    Lyu X, Chen S, Shi H et al.. “Development and validation of a predictive model for septic shock in maternal sepsis: a retrospective cohort study in a single referral center.” BMC pregnancy and childbirth (2026). PMID: 42252422 ↗

    L2COHORTCited in: History and Evolution of Treatment
  362. [362]

    Çelik FH, Eren EE, Baykan N et al.. “Elderly patients with healthcare-associated infections in the emergency department: clinical characteristics and risk factors for septic shock: a retrospective study.” BMC geriatrics (2026). PMID: 42026516 ↗

    L2COHORTCited in: History and Evolution of Treatment
  363. [363]

    Fage N, Demiselle J, Seegers V et al.. “Effects of mean arterial pressure target on mottling and arterial lactate normalization in patients with septic shock: a post hoc analysis of the SEPSISPAM randomized trial.” Annals of intensive care (2022). PMID: 35984574 ↗

    L2OTHERCited in: History and Evolution of Treatment
  364. [364]

    Gonzalez FA, Bacariza J, Varudo AR et al.. “Sepsis-induced myocardial dysfunction diagnosed with strain versus non-strain echocardiography parameters: incidence, evolution and association with prognosis.” Annals of intensive care (2025). PMID: 40999250 ↗

    L2OTHERCited in: History and Evolution of Treatment
  365. [365]

    Hohn A, Balfer N, Heising B et al.. “Adherence to a procalcitonin-guided antibiotic treatment protocol in patients with severe sepsis and septic shock.” Annals of intensive care (2018). PMID: 29869120 ↗

    L2OTHERCited in: History and Evolution of Treatment
  366. [366]

    Helms J, Merdji H, Loewert S et al.. “Disseminated intravascular coagulation is strongly associated with severe acute kidney injury in patients with septic shock.” Annals of intensive care (2023). PMID: 38038826 ↗

    L2OTHERCited in: History and Evolution of Treatment
  367. [367]

    Peschanski N, Chenevier-Gobeaux C, Mzabi L et al.. “Prognostic value of PCT in septic emergency patients.” Annals of intensive care (2016). PMID: 27207179 ↗

    L2OTHERCited in: History and Evolution of Treatment
  368. [368]

    Panitchote A, Mehkri O, Hastings A et al.. “Factors associated with acute kidney injury in acute respiratory distress syndrome.” Annals of intensive care (2019). PMID: 31264042 ↗

    L2OTHERCited in: History and Evolution of Treatment
  369. [369]

    Jouan Y, Grammatico-Guillon L, Teixera N et al.. “Healthcare trajectories before and after critical illness: population-based insight on diverse patients clusters.” Annals of intensive care (2019). PMID: 31707487 ↗

    L2OTHERCited in: History and Evolution of Treatment
  370. [370]

    Brierley J, Carcillo JA, Choong K et al.. “Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine.” Critical care medicine (2009). PMID: 19325359 ↗

    L1GUIDELINECited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  371. [371]

    Wacker DA, Burton SL, Berger JP et al.. “Evaluating Vitamin C in Septic Shock: A Randomized Controlled Trial of Vitamin C Monotherapy.” Critical care medicine (2022). PMID: 34982738 ↗

    L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  372. [372]

    Grau T, Bonet A, Miñambres E et al.. “The effect of L-alanyl-L-glutamine dipeptide supplemented total parenteral nutrition on infectious morbidity and insulin sensitivity in critically ill patients.” Critical care medicine (2011). PMID: 21336131 ↗

    L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Complications & Iatrogenesis
  373. [373]

    Trof RJ, Beishuizen A, Cornet AD et al.. “Volume-limited versus pressure-limited hemodynamic management in septic and nonseptic shock.” Critical care medicine (2012). PMID: 22202713 ↗

    L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  374. [374]

    Payen JF, Dupuis C, Trouve-Buisson T et al.. “Corticosteroid after etomidate in critically ill patients: a randomized controlled trial.” Critical care medicine (2012). PMID: 21926601 ↗

    L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  375. [375]

    Warrillow S, Egi M, Bellomo R. “Randomized, double-blind, placebo-controlled crossover pilot study of a potassium channel blocker in patients with septic shock.” Critical care medicine (2006). PMID: 16484892 ↗

    L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  376. [376]

    Pontes-Arruda A, Aragão AM, Albuquerque JD. “Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock.” Critical care medicine (2006). PMID: 16850002 ↗

    L4RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  377. [377]

    Park CHL, de Almeida JP, de Oliveira GQ et al.. “Lactated Ringer's Versus 4% Albumin on Lactated Ringer's in Early Sepsis Therapy in Cancer Patients: A Pilot Single-Center Randomized Trial.” Critical care medicine (2019). PMID: 31356475 ↗

    L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  378. [378]

    Lauzier F, Lévy B, Lamarre P et al.. “Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial.” Intensive care medicine (2006). PMID: 17019548 ↗

    L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  379. [379]

    Young P, Mackle D, Bellomo R et al.. “Conservative oxygen therapy for mechanically ventilated adults with sepsis: a post hoc analysis of data from the intensive care unit randomized trial comparing two approaches to oxygen therapy (ICU-ROX).” Intensive care medicine (2019). PMID: 31748836 ↗

    L2RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  380. [380]

    Quenot JP, Binquet C, Vinsonneau C et al.. “Very high volume hemofiltration with the Cascade system in septic shock patients.” Intensive care medicine (2015). PMID: 26431720 ↗

    L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  381. [381]

    Boussekey N, Chiche A, Faure K et al.. “A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock.” Intensive care medicine (2008). PMID: 18542921 ↗

    L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  382. [382]

    Zhang Z, Ni H, Qian Z. “Effectiveness of treatment based on PiCCO parameters in critically ill patients with septic shock and/or acute respiratory distress syndrome: a randomized controlled trial.” Intensive care medicine (2015). PMID: 25605469 ↗

    L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Complications & Iatrogenesis
  383. [383]

    Radrizzani D, Bertolini G, Facchini R et al.. “Early enteral immunonutrition vs. parenteral nutrition in critically ill patients without severe sepsis: a randomized clinical trial.” Intensive care medicine (2006). PMID: 16788808 ↗

    L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  384. [384]

    Chen C, Kollef MH. “Targeted Fluid Minimization Following Initial Resuscitation in Septic Shock: A Pilot Study.” Chest (2015). PMID: 26291900 ↗

    L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Complications & Iatrogenesis
  385. [385]

    Munch MW, Myatra SN, Vijayaraghavan BKT et al.. “Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial.” JAMA (2021). PMID: 34673895 ↗

    L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  386. [386]

    Tadié JM, Locher C, Maamar A et al.. “Enteral citrulline supplementation versus placebo on SOFA score on day 7 in mechanically ventilated critically ill patients: the IMMUNOCITRE randomized clinical trial.” Critical care (London, England) (2023). PMID: 37784110 ↗

    L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  387. [387]

    Piotti A, Novelli D, Meessen JMTA et al.. “Endothelial damage in septic shock patients as evidenced by circulating syndecan-1, sphingosine-1-phosphate and soluble VE-cadherin: a substudy of ALBIOS.” Critical care (London, England) (2021). PMID: 33741039 ↗

    L3RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  388. [388]

    Rehberg S, Ertmer C, Lange M et al.. “Role of selective V2-receptor-antagonism in septic shock: a randomized, controlled, experimental study.” Critical care (London, England) (2010). PMID: 21054850 ↗

    L5RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  389. [389]

    Barbar SD, Bourredjem A, Trusson R et al.. “Differential effect on mortality of the timing of initiation of renal replacement therapy according to the criteria used to diagnose acute kidney injury: an IDEAL-ICU substudy.” Critical care (London, England) (2023). PMID: 37592355 ↗

    L2RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  390. [390]

    Morelli A, Ertmer C, Rehberg S et al.. “Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study.” Critical care (London, England) (2009). PMID: 19664253 ↗

    L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  391. [391]

    Cioccari L, Luethi N, Bailey M et al.. “The effect of dexmedetomidine on vasopressor requirements in patients with septic shock: a subgroup analysis of the Sedation Practice in Intensive Care Evaluation [SPICE III] Trial.” Critical care (London, England) (2020). PMID: 32678054 ↗

    L2RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  392. [392]

    Adlbrecht C, Wurm R, Depuydt P et al.. “Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trial.” Critical care (London, England) (2020). PMID: 32131866 ↗

    L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  393. [393]

    Donaldson LH, Devaux A, White KC et al.. “Hydrocortisone and Risk Factors for Kidney Replacement Therapy in Septic Shock.” JAMA network open (2025). PMID: 40423970 ↗

    L2RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
  394. [394]

    Boehm LM, Danesh V, Eaton TL et al.. “Multidisciplinary ICU Recovery Clinic Visits: A Qualitative Analysis of Patient-Provider Dialogues.” Chest (2022). PMID: 36243061 ↗

    L4TRIAL_NONRANDOMCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS), Prevention, Screening and Post-ICU Surveillance
  395. [395]

    Pfister D, Siegemund M, Dell-Kuster S et al.. “Cerebral perfusion in sepsis-associated delirium.” Critical care (London, England) (2008). PMID: 18457586 ↗

    L2TRIAL_NONRANDOMCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS), Special Populations
  396. [396]

    De Jonghe B, Bastuji-Garin S, Durand MC et al.. “Respiratory weakness is associated with limb weakness and delayed weaning in critical illness.” Critical care medicine (2007). PMID: 17855814 ↗

    L2OTHERCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
  397. [397]

    Vieira JM, Castro I, Curvello-Neto A et al.. “Effect of acute kidney injury on weaning from mechanical ventilation in critically ill patients.” Critical care medicine (2007). PMID: 17080002 ↗

    L3OTHERCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
  398. [398]

    Patel S, Stollings JL, Casey JD et al.. “Identifying Predictors of Extubation on the day of Passing an SBT in Critically ill Adults.” Journal of intensive care medicine (2023). PMID: 36648173 ↗

    L3TRIAL_NONRANDOMCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
  399. [399]

    Liu K, Kotani T, Nakamura K et al.. “Effects of evidence-based ICU care on long-term outcomes of patients with sepsis or septic shock (ILOSS): protocol for a multicentre prospective observational cohort study in Japan.” BMJ open (2022). PMID: 35351710 ↗

    L5TRIAL_NONRANDOMCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
  400. [400]

    Hanajima T, Kawazoe Y, Morimoto T et al.. “Early Rehabilitation for Patients with Septic Shock Associated with Mobilization During Their Intensive Care Unit Stay Without Worsening Mortality: A Multicenter, Prospective, Cohort Study.” Journal of intensive care medicine (2025). PMID: 40611676 ↗

    L2COHORTCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
  401. [401]

    Vondeling AM, Knol W, Egberts TCG et al.. “Anticholinergic drug exposure at intensive care unit admission affects the occurrence of delirium. A prospective cohort study.” European journal of internal medicine (2020). PMID: 32487370 ↗

    L2COHORTCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
  402. [402]

    Schubert M, Bettex D, Steiger P et al.. “Implementation of a multiprofessional, multicomponent delirium management guideline in two intensive care units, and its effect on patient outcomes and nurse workload: a pre-post design retrospective cohort study.” Swiss medical weekly (2020). PMID: 31986217 ↗

    L2COHORTCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
  403. [403]

    Chang P, Liao Y, Guan J et al.. “Combined Treatment With Hydrocortisone, Vitamin C, and Thiamine for Sepsis and Septic Shock: A Randomized Controlled Trial.” Chest (2020). PMID: 32243943 ↗

    L1RCTCited in: Complications & Iatrogenesis
  404. [404]

    Shah AD, MacCallum NS, Harris S et al.. “Descriptors of Sepsis Using the Sepsis-3 Criteria: A Cohort Study in Critical Care Units Within the U.K. National Institute for Health Research Critical Care Health Informatics Collaborative.” Critical care medicine (2021). PMID: 34259454 ↗

    L2COHORTCited in: Complications & Iatrogenesis
  405. [405]

    Frencken JF, van Vught LA, Peelen LM et al.. “An Unbalanced Inflammatory Cytokine Response Is Not Associated With Mortality Following Sepsis: A Prospective Cohort Study.” Critical care medicine (2017). PMID: 28257334 ↗

    L2COHORTCited in: Complications & Iatrogenesis
  406. [406]

    Seligman R, Papassotiriou J, Morgenthaler NG et al.. “Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia.” Critical care (London, England) (2008). PMID: 18252006 ↗

    L2TRIAL_NONRANDOMCited in: Complications & Iatrogenesis
  407. [407]

    Pichon N, Amiel JB, François B et al.. “Efficacy of and tolerance to mild induced hypothermia after out-of-hospital cardiac arrest using an endovascular cooling system.” Critical care (London, England) (2007). PMID: 17598898 ↗

    L4TRIAL_NONRANDOMCited in: Complications & Iatrogenesis
  408. [408]

    Ramanathan K, Yeo N, Alexander P et al.. “Role of extracorporeal membrane oxygenation in children with sepsis: a systematic review and meta-analysis.” Critical care (London, England) (2020). PMID: 33287861 ↗

    L1SR_OBSCited in: Complications & Iatrogenesis
  409. [409]

    Jamme M, Daviaud F, Charpentier J et al.. “Time Course of Septic Shock in Immunocompromised and Nonimmunocompromised Patients.” Critical care medicine (2017). PMID: 28937407 ↗

    L2OTHERCited in: Complications & Iatrogenesis
  410. [410]

    Péju E, Llitjos JF, Charpentier J et al.. “Impact of Blood Product Transfusions on the Risk of ICU-Acquired Infections in Septic Shock.” Critical care medicine (2021). PMID: 33591005 ↗

    L2OTHERCited in: Complications & Iatrogenesis
  411. [411]

    Monneret G, Lafon T, Gossez M et al.. “Monocyte HLA-DR expression in septic shock patients: insights from a 20-year real-world cohort of 1023 cases.” Intensive care medicine (2025). PMID: 40986015 ↗

    L2OTHERCited in: Complications & Iatrogenesis
  412. [412]

    Mentzelopoulos SD, Pratikaki M, Platsouka E et al.. “Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa.” Intensive care medicine (2007). PMID: 17549457 ↗

    L3OTHERCited in: Complications & Iatrogenesis
  413. [413]

    Damas P, Layios N, Seidel L et al.. “Severity of ICU-acquired pneumonia according to infectious microorganisms.” Intensive care medicine (2011). PMID: 21614638 ↗

    L2OTHERCited in: Complications & Iatrogenesis
  414. [414]

    Grimaldi D, Louis S, Pène F et al.. “Profound and persistent decrease of circulating dendritic cells is associated with ICU-acquired infection in patients with septic shock.” Intensive care medicine (2011). PMID: 21805160 ↗

    L2OTHERCited in: Complications & Iatrogenesis
  415. [415]

    Morel J, Casoetto J, Jospé R et al.. “De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit.” Critical care (London, England) (2010). PMID: 21167047 ↗

    L2COHORTCited in: Complications & Iatrogenesis
  416. [416]

    Rademacher J, Ewig S, Grabein B et al.. “Key summary of German national guideline for adult patients with nosocomial pneumonia- Update 2024 Funding number at the Federal Joint Committee (G-BA): 01VSF22007.” Infection (2024). PMID: 39115698 ↗

    L1GUIDELINECited in: Complications & Iatrogenesis
  417. [417]

    Tumbarello M, De Pascale G, Trecarichi EM et al.. “Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria.” Chest (2013). PMID: 23989805 ↗

    L3OTHERCited in: Complications & Iatrogenesis
  418. [418]

    Gurnani PK, Barlow B, Boling B et al.. “Major Publications in the Critical Care Pharmacotherapy Literature: 2022.” Critical care explorations (2023). PMID: 37753239 ↗

    L5SR_OBSCited in: Complications & Iatrogenesis, Prevention, Screening and Post-ICU Surveillance
  419. [419]

    Kubo K, Kondo Y, Yoshimura J et al.. “Short- versus prolonged-course antibiotic therapy for sepsis or infectious diseases in critically ill adults: a systematic review and meta-analysis.” Infectious diseases (London, England) (2021). PMID: 34772325 ↗

    L1SR_OBSCited in: Complications & Iatrogenesis
  420. [420]

    Nair GB, Niederman MS. “Year in review 2013: Critical Care--respiratory infections.” Critical care (London, England) (2014). PMID: 25672674 ↗

    L5REVIEW_NARRATIVECited in: Complications & Iatrogenesis, Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  421. [421]

    Depuydt PO, Vandijck DM, Bekaert MA et al.. “Determinants and impact of multidrug antibiotic resistance in pathogens causing ventilator-associated-pneumonia.” Critical care (London, England) (2008). PMID: 19014695 ↗

    L2OTHERCited in: Complications & Iatrogenesis
  422. [422]

    Bassetti M, Giacobbe DR, Vena A et al.. “Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project.” Critical care (London, England) (2019). PMID: 31200780 ↗

    L2OTHERCited in: Complications & Iatrogenesis
  423. [423]

    Masson S, Caironi P, Fanizza C et al.. “Sequential N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin Measurements During Albumin Replacement in Patients With Severe Sepsis or Septic Shock.” Critical care medicine (2016). PMID: 26571184 ↗

    L1RCTCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  424. [424]

    Trusson R, Brunot V, Larcher R et al.. “Short- and Long-Term Outcome of Chronic Dialyzed Patients Admitted to the ICU and Assessment of Prognosis Factors: Results of a 6-Year Cohort Study.” Critical care medicine (2020). PMID: 32697507 ↗

    L2COHORTCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  425. [425]

    Estenssoro E, Kanoore Edul VS, Loudet CI et al.. “Predictive Validity of Sepsis-3 Definitions and Sepsis Outcomes in Critically Ill Patients: A Cohort Study in 49 ICUs in Argentina.” Critical care medicine (2018). PMID: 29742584 ↗

    L2COHORTCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  426. [426]

    Palizas F, Dubin A, Regueira T et al.. “Gastric tonometry versus cardiac index as resuscitation goals in septic shock: a multicenter, randomized, controlled trial.” Critical care (London, England) (2009). PMID: 19335912 ↗

    L1RCTCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  427. [427]

    Merouani M, Guignard B, Vincent F et al.. “Norepinephrine weaning in septic shock patients by closed loop control based on fuzzy logic.” Critical care (London, England) (2008). PMID: 19068113 ↗

    L1RCTCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  428. [428]

    Behnes M, Bertsch T, Lepiorz D et al.. “Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment.” Critical care (London, England) (2014). PMID: 25190134 ↗

    L2TRIAL_NONRANDOMCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  429. [429]

    Dong X, Liu Q, Zheng Q et al.. “Alterations of B Cells in Immunosuppressive Phase of Septic Shock Patients.” Critical care medicine (2020). PMID: 32304414 ↗

    L2OTHERCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  430. [430]

    Gleeson PJ, Crippa IA, Mongkolpun W et al.. “Renin as a Marker of Tissue-Perfusion and Prognosis in Critically Ill Patients.” Critical care medicine (2019). PMID: 30653055 ↗

    L2OTHERCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  431. [431]

    Galbois A, Aegerter P, Martel-Samb P et al.. “Improved prognosis of septic shock in patients with cirrhosis: a multicenter study*.” Critical care medicine (2014). PMID: 24732239 ↗

    L3OTHERCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  432. [432]

    Lemiale V, Pons S, Mirouse A et al.. “Sepsis and Septic Shock in Patients With Malignancies: A Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique Study.” Critical care medicine (2020). PMID: 32317596 ↗

    L3OTHERCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  433. [433]

    Meissner A, Genga KR, Studart FS et al.. “Epidemiology of and factors associated with end-of-life decisions in a surgical intensive care unit.” Critical care medicine (2010). PMID: 20068464 ↗

    L2OTHERCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  434. [434]

    Orlikowski D, Sharshar T, Porcher R et al.. “Prognosis and risk factors of early onset pneumonia in ventilated patients with Guillain-Barré syndrome.” Intensive care medicine (2006). PMID: 17019557 ↗

    L2OTHERCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  435. [435]

    Bedos JP, Varon E, Porcher R et al.. “Host-pathogen interactions and prognosis of critically ill immunocompetent patients with pneumococcal pneumonia: the nationwide prospective observational STREPTOGENE study.” Intensive care medicine (2018). PMID: 30456466 ↗

    L2OTHERCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  436. [436]

    Vandijck DM, Benoit DD, Depuydt PO et al.. “Impact of recent intravenous chemotherapy on outcome in severe sepsis and septic shock patients with hematological malignancies.” Intensive care medicine (2008). PMID: 18214437 ↗

    L3OTHERCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  437. [437]

    Coslovsky M, Takala J, Exadaktylos AK et al.. “A clinical prediction model to identify patients at high risk of death in the emergency department.” Intensive care medicine (2015). PMID: 25792208 ↗

    L2OTHERCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  438. [438]

    Chang Y, Oh JH, Oh DK et al.. “Culture-negative sepsis may be a different entity from culture-positive sepsis: a prospective nationwide multicenter cohort study.” Critical care (London, England) (2024). PMID: 39587586 ↗

    L2COHORTCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  439. [439]

    Montravers P, Kantor E, Constantin JM et al.. “Epidemiology and prognosis of anti-infective therapy in the ICU setting during acute pancreatitis: a cohort study.” Critical care (London, England) (2019). PMID: 31805988 ↗

    L3COHORTCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  440. [440]

    White AC, Joseph B, Gireesh A et al.. “Terminal withdrawal of mechanical ventilation at a long-term acute care hospital: comparison with a medical ICU.” Chest (2009). PMID: 19429725 ↗

    L3OTHERCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  441. [441]

    García-Aguilera MF, Yu-Liu Y, Alexander-León H et al.. “Mortality in Cancer Patients with Septic Shock in Intensive Care: Systematic Review and Meta-Analysis.” Journal of intensive care medicine (2025). PMID: 40953035 ↗

    L1SR_OBSCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  442. [442]

    Alqeeq BF, Ayyad M, Albandak M et al.. “The clinical significance of thrombocytopenia in sepsis and septic shock: a systematic review and meta-analysis.” BMC anesthesiology (2025). PMID: 40597659 ↗

    L1SR_OBSCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  443. [443]

    Chen Y, Jiang H, Wei Y et al.. “Blood pressure response index and clinical outcomes in patients with septic shock: a multicenter cohort study.” EBioMedicine (2024). PMID: 39059317 ↗

    L3COHORTCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  444. [444]

    Tao X, Ye S. “Risk factors for invasive mechanical ventilation, extracorporeal membrane oxygenation, and mortality in children with severe adenovirus infection in the pediatric intensive care unit: a retrospective study.” BMC pediatrics (2025). PMID: 40296021 ↗

    L3COHORTCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
  445. [445]

    Fujii T, Ganeko R, Kataoka Y et al.. “Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis.” Intensive care medicine (2017). PMID: 29204670 ↗

    L1SR_OBSCited in: Special Populations
  446. [446]

    Vincent JL, Sakr Y, Sprung CL et al.. “Sepsis in European intensive care units: results of the SOAP study.” Critical care medicine (2006). PMID: 16424713 ↗

    L2OTHERCited in: Special Populations
  447. [447]

    Geri G, Vignon P, Aubry A et al.. “Cardiovascular clusters in septic shock combining clinical and echocardiographic parameters: a post hoc analysis.” Intensive care medicine (2019). PMID: 30888443 ↗

    L2OTHERCited in: Special Populations
  448. [448]

    Tissot F, Lamoth F, Hauser PM et al.. “β-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis.” American journal of respiratory and critical care medicine (2013). PMID: 23782027 ↗

    L2OTHERCited in: Special Populations
  449. [449]

    Tolsma V, Schwebel C, Azoulay E et al.. “Sepsis severe or septic shock: outcome according to immune status and immunodeficiency profile.” Chest (2014). PMID: 25033349 ↗

    L2OTHERCited in: Special Populations
  450. [450]

    Dmello D, Taylor S, O'Brien J et al.. “Outcomes of etomidate in severe sepsis and septic shock.” Chest (2010). PMID: 20651024 ↗

    L3OTHERCited in: Special Populations
  451. [451]

    Whitson MR, Mo E, Nabi T et al.. “Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock.” Chest (2016). PMID: 26953217 ↗

    L3OTHERCited in: Special Populations
  452. [452]

    Kaukonen KM, Bailey M, Suzuki S et al.. “Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012.” JAMA (2014). PMID: 24638143 ↗

    L2OTHERCited in: Special Populations
  453. [453]

    Ferrer R, Artigas A, Levy MM et al.. “Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain.” JAMA (2008). PMID: 18492971 ↗

    L2OTHERCited in: Special Populations
  454. [454]

    Mokart D, Bianchi A, Ronflé R et al.. “Determinants of Septic Shock and 90-Day Mortality After Postoperative Healthcare-Associated Intra-Abdominal Infection: The Sepsi-Pop Study, a Multicenter Retrospective Study.” Shock (Augusta, Ga.) (2026). PMID: 41949841 ↗

    L3COHORTCited in: Special Populations
  455. [455]

    Şahinoğlu MS, Kökkızıl SÖ, Tarakçı A et al.. “Prognostic factors for mortality in critically ill patients with infections caused by carbapenem-resistant gram-negative pathogens treated with ceftazidime-avibactam: a multicenter retrospective study.” BMC infectious diseases (2026). PMID: 41882581 ↗

    L4COHORTCited in: Special Populations
  456. [456]

    Chen Q, Zeng J, Zhong L et al.. “From proteomics to colloidal gold tests for urinary thrombomodulin: a prospective cohort study on accurate sepsis screening.” Frontiers in cellular and infection microbiology (2026). PMID: 41878263 ↗

    L3COHORTCited in: Special Populations
  457. [457]

    Wattanarat B, Foocharoen C, Panitchote A. “Clinical predictors of mortality in critically ill systemic sclerosis patients: a 6-year retrospective cohort study.” Rheumatology (Oxford, England) (2026). PMID: 41507092 ↗

    L4COHORTCited in: Special Populations
  458. [458]

    Shorr AF, Williams MD. “Venous thromboembolism in critically ill patients. Observations from a randomized trial in sepsis.” Thrombosis and haemostasis (2009). PMID: 19132200 ↗

    L1RCTCited in: Prevention, Screening and Post-ICU Surveillance
  459. [459]

    Monti G, Konkayev A, Carta S et al.. “High dose esomeprazole as an anti-inflammatory agent in sepsis: Protocol for a randomized controlled trial.” Contemporary clinical trials (2023). PMID: 37625587 ↗

    L5TRIAL_NONRANDOMCited in: Prevention, Screening and Post-ICU Surveillance
  460. [460]

    Karlsson H, Afrasiabi A, Ohlsson M et al.. “Treating shock with norepinephrine administered in midline catheters in an intermediary care unit: a retrospective cohort study.” BMJ open (2024). PMID: 39806688 ↗

    L4COHORTCited in: Prevention, Screening and Post-ICU Surveillance
  461. [461]

    Corriero A, Soloperto R, Giglio M et al.. “Probiotics to reduce ventilator-associated pneumonia in adults with acute non‑anoxic brain injury: Study Protocol for a Double-Blind Multicenter Randomized International Clinical Trial (PROACT).” Trials (2025). PMID: 41214813 ↗

    L5TRIAL_NONRANDOMCited in: Prevention, Screening and Post-ICU Surveillance
  462. [462]

    Kofoed A, Perner A, Marker S et al.. “Effects of simulated sample sizes on mortality estimates-Protocol for a study in 3 randomised ICU trials.” Acta anaesthesiologica Scandinavica (2019). PMID: 31032881 ↗

    L5TRIAL_NONRANDOMCited in: Prevention, Screening and Post-ICU Surveillance

Revision History

All updates applied to this page

Loading revisions…